

Immune checkpoint inhibitors: recent progress and potential

Experimental and Molecular Medicine
50, 1-11

DOI: [10.1038/s12276-018-0191-1](https://doi.org/10.1038/s12276-018-0191-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	2.6	10
2	Are mimotope vaccines a good alternative to monoclonal antibodies?. <i>Immunotherapy</i> , 2019, 11, 795-800.	2.0	9
3	Chronic Implant-Related Bone Infectionsâ€”Can Immune Modulation be a Therapeutic Strategy?. <i>Frontiers in Immunology</i> , 2019, 10, 1724.	4.8	124
4	The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3899.	4.1	21
5	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. <i>Cancer Medicine</i> , 2019, 8, 5399-5413.	2.8	15
6	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3KÎ² Inhibition in PTEN Loss Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6406-6416.	7.0	35
7	Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 1117-1128.	2.0	15
8	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 971.	3.7	87
9	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
10	Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. <i>Medical Oncology</i> , 2019, 36, 72.	2.5	4
11	Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1690.	4.8	71
12	Î²2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 603-610.	2.5	22
13	Hypoxia-inducible factor-2Î± and refractory nscl: Further evidence to support the use of immune-checkpoint inhibitors?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 57, 101815.	2.6	0
14	Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1264-1270.	3.7	2
15	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	30.7	133
16	The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients. <i>International Immunopharmacology</i> , 2019, 74, 105745.	3.8	49
17	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. <i>Drug Resistance Updates</i> , 2019, 45, 13-29.	14.4	82
18	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. <i>Nature Communications</i> , 2019, 10, 4712.	12.8	76

#	ARTICLE	IF	CITATIONS
19	A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. <i>Cancers</i> , 2019, 11, 1562.	3.7	31
20	Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. <i>Clinical Immunology</i> , 2019, 209, 108276.	3.2	17
21	Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2019, 77, 105957.	3.8	32
22	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7906-7923.	10.0	100
23	Immunotherapy and other systemic therapies for cutaneous SCC. <i>Oral Oncology</i> , 2019, 99, 104459.	1.5	17
24	The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2354.	4.8	70
25	B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1928.	2.4	13
26	Role of a novel circulatory RNA-based biomarker panel expression in ovarian cancer. <i>IUBMB Life</i> , 2019, 71, 2031-2047.	3.4	5
27	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	28.4	557
28	MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4287.	4.1	28
29	Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. <i>Vaccines</i> , 2019, 7, 109.	4.4	10
30	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	3.2	31
31	Anal cancer and immunotherapy—are we there yet?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 57-57.	3.0	8
32	Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111741.	5.5	10
33	Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm <i>Echinococcus Granulosus</i> . <i>Frontiers in Pharmacology</i> , 2019, 10, 1137.	3.5	18
34	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2019, 70, 117-126.	6.4	41
35	Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. <i>Genes</i> , 2019, 10, 709.	2.4	71
36	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. <i>Nature Medicine</i> , 2019, 25, 1054-1056.	30.7	773

#	ARTICLE	IF	CITATIONS
37	The Evolving Role of CD8+CD28 ^{hi} Immunosenescent T Cells in Cancer Immunology. International Journal of Molecular Sciences, 2019, 20, 2810.	4.1	105
38	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255.	8.6	577
39	Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells, 2019, 8, 470.	4.1	143
40	Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast Cancer, 2019, 26, 738-747.	2.9	21
41	The Novel Aspects on the Mosaic of Autoimmunity. , 2019, , 7-11.		2
42	The body's civil war: Understanding autoimmune conditions. Independent Nurse, 2019, 2019, 27-30.	0.1	0
43	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	2.0	17
44	Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2019, 380, 1597-1605.	27.0	260
45	Chondroitin Sulfate-Based pH-Sensitive Polymer-Modified Liposomes for Intracellular Antigen Delivery and Induction of Cancer Immunity. Bioconjugate Chemistry, 2019, 30, 1518-1529.	3.6	28
46	Targeting Tumor Microenvironment for Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 840.	4.1	822
47	Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer. ACS Omega, 2019, 4, 18593-18599.	3.5	7
48	Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers, 2019, 11, 1822.	3.7	106
49	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports, 2019, 9, 16662.	3.3	33
50	Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 ⁺ T Cell Subsets in Colorectal Cancer Patients. Frontiers in Immunology, 2019, 10, 2936.	4.8	97
51	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Frontiers in Oncology, 2019, 9, 1366.	2.8	50
52	Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer. Trends in Cancer, 2019, 5, 789-798.	7.4	56
53	Molecular Imaging in Pediatric Brain Tumors. Cancers, 2019, 11, 1853.	3.7	12
54	Red biotechnology: A healthy world. AIP Conference Proceedings, 2019, , .	0.4	1

#	ARTICLE	IF	CITATIONS
55	Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development. <i>Cancers</i> , 2019, 11, 1989.	3.7	18
56	Integrated genomic profiling expands clinical options for patients with cancer. <i>Nature Biotechnology</i> , 2019, 37, 1351-1360.	17.5	103
57	Single-cell immune landscape of human atherosclerotic plaques. <i>Nature Medicine</i> , 2019, 25, 1576-1588.	30.7	540
58	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. <i>Cancers</i> , 2019, 11, 1972.	3.7	8
59	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	9.6	146
60	Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs). <i>Bioconjugate Chemistry</i> , 2020, 31, 28-36.	3.6	45
61	Clinical and Morphological Characteristics of Anti-Programmed Death Ligand 1-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2020, 4, 446-450.	2.4	15
62	Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 108-119.	3.4	187
63	TIGIT as an emerging immune checkpoint. <i>Clinical and Experimental Immunology</i> , 2020, 200, 108-119.	2.6	310
64	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Medicine</i> , 2020, 161, 105853.	2.9	23
65	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. <i>Oral Oncology</i> , 2020, 100, 104477.	1.5	9
66	Toward a Better Understanding of Hepatocellular Carcinoma Immune Infiltrates. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 341-342.	4.5	2
67	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 2105.	4.8	164
68	Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards. <i>Frontiers in Immunology</i> , 2020, 11, 2169.	4.8	14
69	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	2.4	11
70	Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 587460.	4.8	87
71	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	2.1	9
72	Self-Assembly as a Molecular Strategy to Improve Immunotherapy. <i>Accounts of Chemical Research</i> , 2020, 53, 2534-2545.	15.6	31

#	ARTICLE	IF	CITATIONS
73	Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962096501.	0.6	3
74	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. Journal of Biopharmaceutical Statistics, 2020, 30, 979-992.	0.8	11
75	<i>Cordyceps militaris</i> Induces Immunogenic Cell Death and Enhances Antitumor Immunogenic Response in Breast Cancer. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	1.2	6
76	Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting) Tj ETQq1 1 0.784314 rgBT ₆ /Overlook	3.7	6
77	Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. Journal of Autoimmunity, 2020, 115, 102546.	6.5	13
78	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. JACC: CardioOncology, 2020, 2, 599-610.	4.0	69
79	Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Pathology Research and Practice, 2020, 216, 153188.	2.3	5
80	In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. Journal of Translational Autoimmunity, 2020, 3, 100067.	4.0	6
81	Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thoracic Cancer, 2020, 11, 3337-3345.	1.9	12
82	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. International Journal of Molecular Sciences, 2020, 21, 7621.	4.1	12
83	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences, 2020, 21, 7743.	4.1	36
84	The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 7358.	4.1	48
85	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Human Molecular Genetics, 2020, 29, R214-R225.	2.9	3
86	Main Strategies for the Identification of Neoantigens. Cancers, 2020, 12, 2879.	3.7	32
87	Tumor resistance mechanisms and their consequences on T cell activation. Immunological Reviews, 2020, 298, 84-98.	6.0	33
88	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282.	4.1	19
89	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncology, 2020, 109, 104977.	1.5	10
90	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Communications, 2020, 40, 374-379.	9.2	29

#	ARTICLE	IF	CITATIONS
91	Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. Journal of Controlled Release, 2020, 326, 203-221.	9.9	33
92	A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapyâ€‘Related Toxicity: A Primer for the Radiologist. American Journal of Roentgenology, 2020, 215, 770-780.	2.2	4
93	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	4.5	24
94	PK/PD-driven starting and effective human dose determination for immuno-oncology drugs. , 2020, , 657-667.		0
95	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€‘BAM, TLR Ligands, and Antiâ€‘CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044.	3.2	11
96	QSPâ€‘O: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immunoâ€‘Oncology Applications. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 484-497.	2.5	34
97	Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 8627.	4.1	51
98	Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection. Cancers, 2020, 12, 3383.	3.7	11
99	The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?. International Journal of Molecular Sciences, 2020, 21, 8678.	4.1	32
100	Fc-Engineering for Modulated Effector Functionsâ€‘Improving Antibodies for Cancer Treatment. Antibodies, 2020, 9, 64.	2.5	93
101	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392.		27
102	Ecological and Evolutionary Consequences of Anticancer Adaptations. IScience, 2020, 23, 101716.	4.1	10
103	A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer. Frontiers in Pharmacology, 2020, 11, 585255.	3.5	21
104	Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy. Seminars in Immunology, 2020, 49, 101434.	5.6	7
105	SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 3521.	3.7	7
106	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	2.8	5
107	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers, 2020, 12, 3301.	3.7	22
108	Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. Cancers, 2020, 12, 3550.	3.7	12

#	ARTICLE	IF	CITATIONS
109	Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 9023.	4.1	16
110	Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response. Cancers, 2020, 12, 3600.	3.7	9
111	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
112	Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. Journal of Immunology Research, 2020, 2020, 1-9.	2.2	2
113	Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics, 2020, 12, 1871-1882.	2.1	11
114	Inhibitory Receptor Trap: A Platform for Discovery of Inhibitory Receptors That Utilize Inositol Lipid and Phosphotyrosine Phosphatase Effectors. Frontiers in Immunology, 2020, 11, 592329.	4.8	5
115	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. International Journal of Nanomedicine, 2020, Volume 15, 5719-5743.	6.7	23
116	Different MDSC Activity of G-CSF/Dexamethasone Mobilized Neutrophils: Benefits to the Patient?. Frontiers in Oncology, 2020, 10, 1110.	2.8	4
117	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2403-2408.	4.2	10
118	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34, 3413-3419.	7.2	42
119	The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer, 2020, 20, 738.	2.6	9
120	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. Cancers, 2020, 12, 2237.	3.7	71
121	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
122	Germline genomes have a dominant heritable contribution to cancer immune evasion and immunotherapy response. Quantitative Biology, 2020, 8, 216-227.	0.5	2
123	Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Biomarkers in Medicine, 2020, 14, 929-932.	1.4	0
124	COVID-19 and Cardiovascular Health Among Patients with Cancer. Current Cardiology Reports, 2020, 22, 171.	2.9	8
125	Inducing multiple antibodies to treat squamous cell esophageal carcinoma. BMC Cancer, 2020, 20, 1007.	2.6	3
126	Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. Toxins, 2020, 12, 658.	3.4	14

#	ARTICLE	IF	CITATIONS
127	RNA-electroporated T cells for cancer immunotherapy. <i>Oncolimmunology</i> , 2020, 9, 1792625.	4.6	6
128	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1251-1262.	3.4	16
129	Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 250.	17.1	86
130	Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3052.	3.7	13
131	Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4831.	3.8	69
132	Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. , 2020, 8, e001141.		31
133	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1183-1193.	2.0	12
134	Immune infiltrating cells in duodenal cancers. <i>Journal of Translational Medicine</i> , 2020, 18, 340.	4.4	3
135	Targeting TANK-binding kinase 1 (TBK1) in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1065-1078.	3.4	26
136	In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α -Mannosyl-Functionalized Cationic Nanohydrogel Particles. <i>Cells</i> , 2020, 9, 1905.	4.1	36
137	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1233-1241.	0.5	11
138	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	4.2	125
139	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. <i>Lancet Oncology</i> , The, 2020, 21, e419-e430.	10.7	128
140	Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. <i>Biomedicines</i> , 2020, 8, 327.	3.2	9
141	The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. <i>Vaccines</i> , 2020, 8, 529.	4.4	9
142	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. <i>In Vivo</i> , 2020, 34, 2641-2646.	1.3	15
143	Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. <i>BMJ Case Reports</i> , 2020, 13, e235265.	0.5	18
144	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. <i>Frontiers in Immunology</i> , 2020, 11, 1568.	4.8	20

#	ARTICLE	IF	CITATIONS
145	Leptomeningeal Carcinomatosis. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 613-625.	1.7	21
146	Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. <i>Pharmaceutics</i> , 2020, 12, 754.	4.5	12
147	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 758.	4.5	6
148	<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	2.0	12
149	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. <i>Cancers</i> , 2020, 12, 2334.	3.7	15
150	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
151	Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. <i>Cells</i> , 2020, 9, 1896.	4.1	73
152	Repositioning of Immunomodulators: A Ray of Hope for Alzheimerâ€™s Disease?. <i>Frontiers in Neuroscience</i> , 2020, 14, 614643.	2.8	16
153	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	3.2	34
154	Resveratrol Activates Natural Killer Cells through Akt- and mTORC2-Mediated c-Myb Upregulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9575.	4.1	16
155	The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors. <i>Cancer Gene Therapy</i> , 2020, 28, 1035-1045.	4.6	1
156	Immune gene therapy of cancer. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1679-1690.	0.9	9
157	Progressive multifocal leukoencephalopathy treated with interleukin-7. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100049.	0.5	2
158	Immune checkpoint markers and antiâ€™CD20â€™mediated NK cell activation. <i>Journal of Leukocyte Biology</i> , 2020, 110, 723-733.	3.3	2
159	Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. <i>American Journal of Roentgenology</i> , 2021, 217, 613-622.	2.2	9
160	TGF-Î² Mediated Immune Evasion in Cancerâ€™Spotlight on Cancer-Associated Fibroblasts. <i>Cancers</i> , 2020, 12, 3650.	3.7	37
161	Living with Metastatic Cancer: A Roadmap for Future Research. <i>Cancers</i> , 2020, 12, 3684.	3.7	26
162	Acquired lipodystrophy associated with immune checkpoint inhibitors. <i>Melanoma Research</i> , 2020, 30, 599-602.	1.2	16

#	ARTICLE	IF	CITATIONS
163	Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology. <i>Epigenomes</i> , 2020, 4, 22.	1.8	6
164	Benchmarking of cell type deconvolution pipelines for transcriptomics data. <i>Nature Communications</i> , 2020, 11, 5650.	12.8	207
165	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	2.5	23
166	The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 524205.	2.8	31
167	Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis. <i>BMC Cancer</i> , 2020, 20, 1062.	2.6	27
168	Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents. <i>Current Clinical Microbiology Reports</i> , 2020, 7, 142-149.	3.4	12
169	Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1740-1744.e9.	0.5	5
170	Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 241-249.	4.4	60
171	The advent of de novo proteins for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 119-128.	6.1	15
172	T Cell Receptor Engineered Lymphocytes for Cancer Therapy. <i>Current Protocols in Immunology</i> , 2020, 129, e97.	3.6	7
173	HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. <i>Journal of Cancer</i> , 2020, 11, 4059-4072.	2.5	65
174	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. <i>Cancers</i> , 2020, 12, 1181.	3.7	69
175	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	2.4	7
176	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	3.8	14
177	Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 28047-28056.	8.0	30
178	Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. <i>Nature Communications</i> , 2020, 11, 2739.	12.8	210
179	Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Journal of Infectious Diseases</i> , 2020, 222, 1902-1909.	4.0	33
180	Functional and metabolic targeting of natural killer cells to solid tumors. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 577-600.	4.4	25

#	ARTICLE	IF	CITATIONS
181	How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology and Oncology, 2020, 13, 45.	17.0	105
182	Recombinant human ulinastatin improves immune dysfunction of dendritic cells in septic mice by inhibiting endoplasmic reticulum stress-related apoptosis. International Immunopharmacology, 2020, 85, 106643.	3.8	7
183	The immunoregulatory function of polyphenols: implications in cancer immunity. Journal of Nutritional Biochemistry, 2020, 85, 108428.	4.2	20
184	Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198.	1.0	19
185	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Medicine, 2020, 12, 47.	8.2	107
186	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers, 2020, 12, 1315.	3.7	18
187	Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Molecular Cell, 2020, 78, 1019-1033.	9.7	450
188	Old dogs, new trick: classic cancer therapies activate cGAS. Cell Research, 2020, 30, 639-648.	12.0	104
189	Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. Expert Opinion on Drug Discovery, 2020, 15, 1223-1232.	5.0	8
190	Outcomes of immunomodulatory and biologic therapy in people living with HIV. Aids, 2020, 34, 1171-1179.	2.2	7
191	NF- κ B and Its Role in Checkpoint Control. International Journal of Molecular Sciences, 2020, 21, 3949.	4.1	45
192	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews, 2020, 88, 102030.	7.7	44
193	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 4030.	4.1	7
194	Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. Journal of Experimental and Clinical Cancer Research, 2020, 39, 112.	8.6	158
195	Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 2247-2257.	4.2	14
196	Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Review of Molecular Diagnostics, 2020, 20, 1027-1037.	3.1	5
197	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Frontiers in Immunology, 2020, 11, 1469.	4.8	58
198	pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000083.	3.2	22

#	ARTICLE	IF	CITATIONS
199	Immunometabolism: new insights and lessons from antigen-directed cellular immune responses. <i>Seminars in Immunopathology</i> , 2020, 42, 279-313.	6.1	37
200	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 348.	4.1	4
201	Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2272-2298.	12.0	147
202	<p><High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1757-1765.	2.0	8
203	Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 143, 19-26.	2.0	81
204	The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia. <i>Hla</i> , 2020, 96, 3-12.	0.6	17
205	A Fatal Case of Pembrolizumab-Induced Myocarditis in Non-Small Cell Lung Cancer. <i>JACC: Case Reports</i> , 2020, 2, 426-430.	0.6	7
206	Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 47-60.	4.4	35
207	A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. <i>Cancer Immunology Research</i> , 2020, 8, 596-608.	3.4	28
208	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. <i>Cancers</i> , 2020, 12, 767.	3.7	2
209	Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. <i>Advanced Science</i> , 2020, 7, 1903410.	11.2	30
210	Next-generation stem cells - ushering in a new era of cell-based therapies. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 463-479.	46.4	161
211	Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration. <i>Neurotherapeutics</i> , 2020, 17, 955-965.	4.4	17
212	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 141.	4.1	35
213	Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 565.	4.1	28
214	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	4.1	39
215	Developing effective combination therapy for pancreatic cancer: An overview. <i>Pharmacological Research</i> , 2020, 155, 104740.	7.1	46
216	New tools to prevent cancer growth and spread: a "Clever" approach. <i>British Journal of Cancer</i> , 2020, 123, 501-509.	6.4	34

#	ARTICLE	IF	CITATIONS
217	Functional categories of immune inhibitory receptors. Nature Reviews Immunology, 2020, 20, 771-780.	22.7	60
218	Exploiting Cancer's Tactics to Make Cancer a Manageable Chronic Disease. Cancers, 2020, 12, 1649.	3.7	3
219	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	10.5	1,136
220	On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. , 2020, 8, e001145.		48
221	Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. Frontiers in Immunology, 2020, 11, 1184.	4.8	65
222	Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. Cancers, 2020, 12, 1699.	3.7	27
223	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.	2.1	62
224	Mycobacteria-Based Vaccines as Immunotherapy for Non-uological Cancers. Cancers, 2020, 12, 1802.	3.7	14
225	Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 635-648.	17.8	172
226	Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093611.	3.2	28
227	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427.	4.1	67
228	Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Proliferation, 2020, 53, e12865.	5.3	43
229	Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. Cells, 2020, 9, 1525.	4.1	13
230	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes, 2020, 11, 703.	2.4	14
231	Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility. American Journal of Reproductive Immunology, 2020, 84, e13296.	1.2	19
232	Regulatory lymphocytes: the dice that resolve the tumor endgame. Applied Cancer Research, 2020, 40, .	1.0	7
233	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers, 2020, 12, 1826.	3.7	46
234	Organoid technology and applications in cancer immunotherapy and precision medicine. Current Opinion in Biotechnology, 2020, 65, 242-247.	6.6	23

#	ARTICLE	IF	CITATIONS
235	Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. <i>Pharmacological Research</i> , 2020, 153, 104683.	7.1	269
236	Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody. <i>RSC Advances</i> , 2020, 10, 8074-8079.	3.6	13
237	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	143
238	Expanding the reach of medical physics: Immunotherapy should be included as part of the curriculum for medical physics education and training. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 6-10.	1.9	0
239	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.9	120
240	Identification of Antigenic Targets. <i>Trends in Cancer</i> , 2020, 6, 299-318.	7.4	6
241	Cholangiocarcinoma: novel therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 345-357.	3.4	25
242	Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 59-65.	0.7	13
243	Analytical Performance of an Immunoprofiling Assay Based on RNA Models. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 555-570.	2.8	6
244	Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins. <i>Seminars in Immunology</i> , 2020, 47, 101392.	5.6	5
245	Yap suppresses T-cell function and infiltration in the tumor microenvironment. <i>PLoS Biology</i> , 2020, 18, e3000591.	5.6	58
246	Peptide-based targeting of immunosuppressive cells in cancer. <i>Bioactive Materials</i> , 2020, 5, 92-101.	15.6	41
247	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	4.1	58
248	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	3.7	311
249	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 643.	3.3	124
250	Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 3122.	4.8	7
251	Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. <i>Targeted Oncology</i> , 2020, 15, 25-35.	3.6	25
252	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. <i>Journal of Translational Medicine</i> , 2020, 18, 49.	4.4	114

#	ARTICLE	IF	CITATIONS
253	Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. Current Cancer Therapy Reviews, 2020, 16, 62-69.	0.3	5
254	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047.	3.7	95
255	A review of the imaging manifestations of immune check point inhibitor toxicities. Clinical Imaging, 2020, 64, 70-79.	1.5	9
256	FS222, a CD137/PD-L1 Tetraivalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Clinical Cancer Research, 2020, 26, 4154-4167.	7.0	44
257	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers, 2020, 12, 751.	3.7	66
258	Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. IUBMB Life, 2020, 72, 1649-1658.	3.4	2
259	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. Cancers, 2020, 12, 915.	3.7	1
260	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Research and Treatment, 2020, 181, 331-338.	2.5	25
261	Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. Current Opinion in Oncology, 2020, 32, 203-209.	2.4	8
262	Towards Physiologically and Tightly Regulated Vectored Antibody Therapies. Cancers, 2020, 12, 962.	3.7	13
263	microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. International Journal of Molecular Sciences, 2020, 21, 2805.	4.1	17
264	Talkinâ€™™ Toxins: From Coleyâ€™™s to Modern Cancer Immunotherapy. Toxins, 2020, 12, 241.	3.4	47
265	Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 150, 102966.	4.4	45
266	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. Frontiers in Physiology, 2020, 11, 154.	2.8	27
267	Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Review of Clinical Pharmacology, 2020, 13, 403-421.	3.1	7
268	Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. , 2020, 8, e000613.		15
269	Comparison of Immune Microenvironment Between Colon and Liver Metastatic Tissue in Colon Cancer Patients with Liver Metastasis. Digestive Diseases and Sciences, 2021, 66, 474-482.	2.3	12
270	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology, 2021, 87, 237-255.	2.4	14

#	ARTICLE	IF	CITATIONS
271	Pathology of triple negative breast cancer. <i>Seminars in Cancer Biology</i> , 2021, 72, 136-145.	9.6	118
272	Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 418-423.	2.4	31
273	Impact of pharmacist-managed immune checkpoint inhibitor toxicities. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 596-600.	0.9	11
274	Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, <i>Helicobacter pylori</i> Gastritis and Celiac Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 191-200.	2.5	23
275	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	8.2	48
276	Characteristic pathological features of keratinocyte death in a case of Stevens-Johnson syndrome manifested by an immune checkpoint inhibitor. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e142-e145.	2.4	8
277	Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. , 2021, 217, 107662.		18
278	Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. <i>Clinical and Translational Oncology</i> , 2021, 23, 110-121.	2.4	9
279	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. <i>Trends in Molecular Medicine</i> , 2021, 27, 75-90.	6.7	5
280	Use of an anti-CD200 blocking antibody improves immune responses to AML <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2021, 193, 155-159.	2.5	15
281	Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 33-43.	2.4	5
282	Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 935-944.	4.2	23
283	Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101525.	1.5	0
284	Immune Checkpoint Inhibitor-Associated Autoimmune Encephalitis. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 115-118.	0.4	3
285	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	7.4	7
286	Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188484.	7.4	11
287	Cancer evolution: A means by which tumors evade treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111016.	5.6	20
288	AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 5-11.	4.1	19

#	ARTICLE	IF	CITATIONS
289	Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 574860.	2.8	13
290	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	4.4	26
291	Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL. <i>Leukemia and Lymphoma</i> , 2021, 62, 992-994.	1.3	3
292	Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 330, 1168-1177.	9.9	17
293	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2021, 16, 381-394.	1.1	12
294	Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis. <i>Clinical and Experimental Immunology</i> , 2021, 204, 78-95.	2.6	10
295	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. <i>BioDrugs</i> , 2021, 35, 61-73.	4.6	1
296	TIM-3 pathway dysregulation and targeting in cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 523-534.	2.4	54
297	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.8	84
298	Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation. <i>International Journal of Cancer</i> , 2021, 148, 1808-1820.	5.1	1
299	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021, 26, 231-241.	3.7	29
300	Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1075-1088.	4.2	18
301	Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells. <i>Cancer Letters</i> , 2021, 497, 212-220.	7.2	30
302	ADARs, RNA editing and more in hematological malignancies. <i>Leukemia</i> , 2021, 35, 346-359.	7.2	10
303	Advances in Magnetic Nanoparticle-Mediated Cancer Immune-Theranostics. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001451.	7.6	59
304	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 311-322.	3.1	10
305	Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2021, 34, 408-416.	5.5	22
306	The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. <i>Journal of Pharmacy Practice</i> , 2021, 34, 386-396.	1.0	4

#	ARTICLE	IF	CITATIONS
307	Machine and deep learning approaches for cancer drug repurposing. <i>Seminars in Cancer Biology</i> , 2021, 68, 132-142.	9.6	122
308	Immune checkpoint molecules: â€œnewâ€ kids on the block of skin photoimmunology. <i>Genes and Diseases</i> , 2021, 8, 1-5.	3.4	0
309	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1267.	3.8	4
310	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
311	Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1071.	4.1	8
312	Antibody-Based Molecular Imaging. , 2021, , 547-562.		0
313	Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. <i>OncolImmunology</i> , 2021, 10, 1958590.	4.6	16
314	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. <i>Frontiers in Immunology</i> , 2020, 11, 612244.	4.8	31
315	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	7.0	67
316	Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. , 2021, , 271-308.		0
317	Intraepithelial Lymphocytes Suppress Intestinal Tumor Growth by Cell-to-Cell Contact via CD103/E-Cadherin Signal. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1483-1503.	4.5	14
318	Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients. <i>Iraqi Journal of Hematology</i> , 2021, 10, 1.	0.1	2
319	IFN- γ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	3.7	17
320	Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. <i>IScience</i> , 2021, 24, 102016.	4.1	32
321	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	10.0	19
322	The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. <i>Cancer Control</i> , 2021, 28, 107327482199743.	1.8	30
323	The Multiple Potential Biomarkers for Predicting Immunotherapy Responseâ€”Finding the Needle in the Haystack. <i>Cancers</i> , 2021, 13, 277.	3.7	16
324	The Road to Effective Cancer Immunotherapyâ€”A Computational Perspective on Tumor Epitopes in Anti-Cancer Immunotherapy. , 2021, , 593-607.		0

#	ARTICLE	IF	CITATIONS
325	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584.	3.4	12
326	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 334.	3.7	44
327	Methods to Study Posttranslational Modification Patterns in Cytotoxic T-Cells and Cancer. Methods in Molecular Biology, 2021, 2325, 137-153.	0.9	1
328	Chelerythrine and Chelidonine Decrease Extracellular Adenosine Improving Cd8 ⁺ T Anti-Tumor Immunity. SSRN Electronic Journal, 0, , .	0.4	0
329	Epithelial and Immune Cell Responses to Helicobacter pylori That Shape the Gastric Tumor Microenvironment. Physiology in Health and Disease, 2021, , 155-197.	0.3	0
330	PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. Cells, 2021, 10, 229.	4.1	8
331	Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy. Cells, 2021, 10, 231.	4.1	34
332	LncRNA as Cancer Biomarkers. Methods in Molecular Biology, 2021, 2348, 27-41.	0.9	14
333	CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics, 2021, 11, 7175-7187.	10.0	34
334	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Advances in Experimental Medicine and Biology, 2021, 1330, 33-54.	1.6	3
335	Summarizing RNA-Seq Data or Differentially Expressed Genes Using Gene Set, Network, or Pathway Analysis. Methods in Molecular Biology, 2021, 2284, 147-179.	0.9	4
336	Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Annals of Translational Medicine, 2021, 9, 129-129.	1.7	24
337	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology, 2021, 10, 1960729.	4.6	8
338	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. Frontiers in Oncology, 2020, 10, 574937.	2.8	29
339	Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nature Protocols, 2021, 16, 1331-1342.	12.0	48
340	Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. Frontiers in Immunology, 2021, 12, 631483.	4.8	5
341	Bladder cancer cell-intrinsic PD-1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Medicine, 2021, 10, 2137-2152.	2.8	26
342	Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World Journal of Clinical Oncology, 2021, 12, 103-114.	2.3	12

#	ARTICLE	IF	CITATIONS
343	Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions. <i>BMJ Case Reports</i> , 2021, 14, e237217.	0.5	16
344	A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. <i>Nature Communications</i> , 2021, 12, 1087.	12.8	62
345	Stimulation and Suppression of the Innate Immune System through Nanotechnology. <i>ACS Applied Nano Materials</i> , 2021, 4, 2303-2316.	5.0	5
346	Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2022, 78, 78-89.	9.6	16
347	Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Nonâ€‘small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 627089.	2.6	9
348	Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. <i>Pharmaceutics</i> , 2021, 13, 257.	4.5	7
349	In Vitro Suppression of T Cell Proliferation Is a Conserved Function of Primary and Immortalized Human Cancer-Associated Fibroblasts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1827.	4.1	11
350	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 860.	3.7	37
351	Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2142.	4.1	6
352	PILE: a candidate prognostic score in cancer patients treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1630-1636.	2.4	14
353	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2755-2763.	7.0	29
354	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	2.8	100
355	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. <i>Nature Communications</i> , 2021, 12, 975.	12.8	26
356	Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 72.	0.8	1
357	Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. <i>Frontiers in Pharmacology</i> , 2021, 12, 572845.	3.5	6
358	Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. <i>Scientific Reports</i> , 2021, 11, 3750.	3.3	22
359	Immunogenic Cell Death Inducing Fluorinated Mitochondriaâ€‘Disrupting Helical Polypeptide Synergizes with PDâ€‘L1 Immune Checkpoint Blockade. <i>Advanced Science</i> , 2021, 8, 2001308.	11.2	31
360	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	1.2	28

#	ARTICLE	IF	CITATIONS
361	Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	3
362	Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature. BMC Endocrine Disorders, 2021, 21, 33.	2.2	5
363	PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation. Cancers, 2021, 13, 555.	3.7	18
364	Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma. Cancers, 2021, 13, 1044.	3.7	8
365	Surprising impact of stromal TILs on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer, 2021, 153, 81-89.	2.0	42
366	Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Annals of Translational Medicine, 2021, 9, 465-465.	1.7	14
367	Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer. , 2021, 9, e001610.		27
369	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology, 2021, 7, 10.	1.7	12
370	Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors. Clinical Transplantation, 2021, 35, e14264.	1.6	3
371	Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics, 2021, 5, 326-337.	2.1	4
372	Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. Frontiers in Endocrinology, 2021, 12, 624686.	3.5	13
373	Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?. Cancers, 2021, 13, 1582.	3.7	11
374	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 641469.	3.7	76
375	Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology and Oncology, 2021, 14, 45.	17.0	293
376	Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity. Journal of Infectious Diseases, 2021, 224, 1599-1604.	4.0	13
377	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. Npj Precision Oncology, 2021, 5, 17.	5.4	23
378	A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mammalian Genome, 2021, 32, 223-231.	2.2	17
379	Endokrynologiczne powikłania nowych terapii przeciwnowotworowych. Postępy Higieny i Medycyny Doswiadczalnej, 2021, 75, 191-198.	0.1	0

#	ARTICLE	IF	CITATIONS
380	Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 255-260.	3.4	16
381	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 589680.	2.8	23
382	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6956.	3.3	3
383	Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 042001.	3.3	6
384	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
385	Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 508-518.	4.4	21
386	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	3.2	7
387	Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1229-1240.	1.4	16
388	The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. <i>European Journal of Pharmacology</i> , 2021, 896, 173921.	3.5	57
389	Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. <i>Endocrinology and Metabolism</i> , 2021, 36, 413-423.	3.0	24
390	Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. <i>Pharmaceutics</i> , 2021, 13, 520.	4.5	25
391	Embracing nanomaterials' interactions with the innate immune system. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1719.	6.1	10
392	The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF). <i>EBioMedicine</i> , 2021, 66, 103325.	6.1	16
393	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	7.2	37
394	Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100039.	4.1	34
395	Challenges and perspectives for immunotherapy in Esophageal cancer: A look to the future (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	3
396	An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2021, 2021, 1-14.	1.3	21
397	Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 654350.	2.8	14

#	ARTICLE	IF	CITATIONS
398	Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	3.6	19
399	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from \pm PD-L1 and include tissue-selective β T cell activation. , 2021, 9, e002051.		12
400	Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2021, 13, 2167.	3.7	11
401	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. <i>Journal of Controlled Release</i> , 2021, 332, 109-126.	9.9	33
402	Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 648580.	4.8	11
403	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3303-3312.	4.2	5
404	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. <i>Oncologist</i> , 2021, 26, e1216-e1225.	3.7	26
405	How to use liquid biopsies to treat patients with cancer. <i>ESMO Open</i> , 2021, 6, 100060.	4.5	43
406	Role of the nervous system in cancers: a review. <i>Cell Death Discovery</i> , 2021, 7, 76.	4.7	59
407	Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 646874.	4.8	6
408	Changing the History of Prostate Cancer with New Targeted Therapies. <i>Biomedicines</i> , 2021, 9, 392.	3.2	16
409	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1006.	4.1	45
410	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	2.4	17
411	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 7490.	3.3	8
412	Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 643255.	4.8	6
413	Strategies for monitoring cell-cell interactions. <i>Nature Chemical Biology</i> , 2021, 17, 641-652.	8.0	59
414	Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators. <i>Current Cancer Drug Targets</i> , 2021, 21, 353-359.	1.6	6
415	Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. <i>Frontiers in Immunology</i> , 2021, 12, 687673.	4.8	59

#	ARTICLE	IF	CITATIONS
416	Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 97, e191-e202.	1.1	26
417	Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. <i>BMC Cancer</i> , 2021, 21, 645.	2.6	70
418	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	3.5	76
419	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	3.3	11
420	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2021, 11, 785.	4.0	9
421	Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. <i>Cancers</i> , 2021, 13, 2498.	3.7	23
422	The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 635-645.	2.5	3
423	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	3.4	25
424	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6902-6923.	6.4	26
425	Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. <i>Biomaterials</i> , 2021, 272, 120791.	11.4	83
426	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	6.9	5
427	Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 22, 554.	1.8	29
428	Organic optical agents for image-guided combined cancer therapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 042009.	3.3	5
429	The abscopal effect of radiation therapy. <i>Future Oncology</i> , 2021, 17, 1683-1694.	2.4	61
431	Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 629330.	3.5	3
432	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIIm)â€”insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	1.9	3
433	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. <i>Cancers</i> , 2021, 13, 2735.	3.7	21
434	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.2	0

#	ARTICLE	IF	CITATIONS
435	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	4.8	32
436	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
437	Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 619821.	2.3	3
438	Recent Progress in Dendritic Cell-Based Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 2495.	3.7	26
439	Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e218065.	5.9	31
440	The influence of monoclonal antibodies for cancer treatment on the endocrine system. <i>Postepy Higieny i Medycyny Doswiadczalnej</i> , 2021, 75, 317-327.	0.1	0
441	Immunotherapies targeting stimulatory pathways and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 78.	17.0	23
442	Cancer Salt Nostalgia. <i>Cells</i> , 2021, 10, 1285.	4.1	5
443	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	7.7	42
444	Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4843.	4.1	8
445	Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. <i>Drug Resistance Updates</i> , 2021, 56, 100752.	14.4	35
446	Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. <i>Cancers</i> , 2021, 13, 2302.	3.7	2
447	The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3629-3642.	4.2	11
448	Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3244-3261.	12.0	41
449	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	4.3	8
450	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	3.7	15
451	Mismatch repair deficiency is rare in bone and soft tissue tumors. <i>Histopathology</i> , 2021, 79, 509-520.	2.9	18
452	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102172.	7.7	27

#	ARTICLE	IF	CITATIONS
453	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab100.	0.2	9
454	TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy. <i>JCI Insight</i> , 2021, 6, .	5.0	14
455	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 649863.	3.5	24
456	Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology. <i>Small Structures</i> , 2021, 2, 2100026.	12.0	7
457	The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 687399.	3.5	32
458	Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2793.	3.7	8
459	Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. <i>ELife</i> , 2021, 10, .	6.0	40
460	MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3. <i>Cell Death Discovery</i> , 2021, 7, 145.	4.7	18
461	Bioinformatics: A beacon of hope in identifying molecular target. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 496-498.	1.3	2
462	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684098.	2.8	41
463	DNA Nanotechnologyâ€Based Biosensors and Therapeutics. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002205.	7.6	51
464	Stoichiometry of multi-specific immune checkpoint RNA Abs for TÂcell activation and tumor inhibition using ultra-stable RNA nanoparticles. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 426-435.	5.1	5
465	A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.	1.2	3
466	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. <i>British Journal of Cancer</i> , 2021, 125, 717-724.	6.4	12
467	VISTA: A Promising Target for Cancer Immunotherapy?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 185-200.	5.8	31
468	Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2021, 52, 302-306.	0.7	0
469	An immune-related model based on INHBA, JAG2 and CCL19 to predict the prognoses of colon cancer patients. <i>Cancer Cell International</i> , 2021, 21, 299.	4.1	4
470	Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. <i>Future Oncology</i> , 2021, 17, 2683-2692.	2.4	2

#	ARTICLE	IF	CITATIONS
471	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters. <i>Frontiers in Immunology</i> , 2021, 12, 690112.	4.8	42
472	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021, 13, 3415.	3.7	15
473	Perioperative clinical trials for glioma: Raising the bar. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 144-150.	1.5	5
474	Severe Demyelinating Polyneuropathy and Cranial Neuropathy During Avelumab Treatment of Metastatic Merkel Cell Carcinoma. <i>Clinical Neuropharmacology</i> , 2021, 44, 193-195.	0.7	4
475	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.	4.5	9
476	Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2021, 8, 73-83.	0.3	2
477	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707198.	3.7	17
478	Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2701-2719.	4.2	8
479	Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center. <i>Cancer Research and Treatment</i> , 2021, 53, 874-880.	3.0	8
480	Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma. <i>Biology</i> , 2021, 10, 674.	2.8	4
481	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. <i>Vaccines</i> , 2021, 9, 807.	4.4	2
482	Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. <i>BMC Cancer</i> , 2021, 21, 817.	2.6	2
483	Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting. <i>World Journal of Stem Cells</i> , 2021, 13, 685-736.	2.8	3
484	Lytic Release of Cellular ATP: Physiological Relevance and Therapeutic Applications. <i>Life</i> , 2021, 11, 700.	2.4	10
485	Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection – A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?. <i>Cells</i> , 2021, 10, 1817.	4.1	8
486	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 678409.	3.5	15
487	Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2021, 14, 1051-1058.	0.7	5
488	Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. <i>Microorganisms</i> , 2021, 9, 1469.	3.6	6

#	ARTICLE	IF	CITATIONS
489	Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes. Journal of Oncology, 2021, 2021, 1-12.	1.3	6
490	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports, 2021, 23, 98.	2.9	34
491	Predictive value of ^{18}F -fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. , 2021, 9, e003079.		5
492	The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. International Journal of Molecular Sciences, 2021, 22, 8036.	4.1	11
493	Lysosomal nitric oxide determines transition from autophagy to ferroptosis after exposure to plasma-activated Ringer's lactate. Redox Biology, 2021, 43, 101989.	9.0	55
494	Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform. Nano Letters, 2021, 21, 6022-6030.	9.1	25
495	Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment. Frontiers in Oncology, 2021, 11, 720125.	2.8	18
496	Targeting Neoepitopes to Treat Solid Malignancies: Immunotherapy. Frontiers in Immunology, 2021, 12, 592031.	4.8	6
497	Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Frontiers in Molecular Neuroscience, 2021, 14, 710171.	2.9	6
498	Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines, 2021, 9, 724.	4.4	27
499	The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. Cancer Letters, 2021, 510, 67-78.	7.2	60
500	Heterogeneous Myeloid Cells in Tumors. Cancers, 2021, 13, 3772.	3.7	30
501	Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers, 2021, 13, 3725.	3.7	7
502	A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy. Cancers, 2021, 13, 3751.	3.7	18
503	GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. , 2021, 9, e003005.		22
504	GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer. Frontiers in Immunology, 2021, 12, 660397.	4.8	13
505	Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update. Brain Sciences, 2021, 11, 1035.	2.3	6
506	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 ⁺ T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1119-1129.	2.8	11

#	ARTICLE	IF	CITATIONS
507	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	2.8	33
508	Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma. <i>Polymers</i> , 2021, 13, 2726.	4.5	6
509	CD47-SIRP α Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. <i>Cancers</i> , 2021, 13, 4261.	3.7	15
510	Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2021, 13, 1271-1282.	2.0	13
511	Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 1066-1075.	9.6	14
512	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. <i>Frontiers in Pharmacology</i> , 2021, 12, 720692.	3.5	20
513	Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. <i>FEBS Letters</i> , 2021, 595, 2290-2302.	2.8	16
514	Photodynamic Therapy for the Treatment and Diagnosis of Cancer—A Review of the Current Clinical Status. <i>Frontiers in Chemistry</i> , 2021, 9, 686303.	3.6	172
515	Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2021, 13, e16829.	0.5	7
516	Enhanced CXCR4 Expression of Human CD8Low T Lymphocytes Is Driven by S1P4. <i>Frontiers in Immunology</i> , 2021, 12, 668884.	4.8	8
517	Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 701429.	3.7	16
518	Sex Differences in Cancer Genomes: Much Learned, More Unknown. <i>Endocrinology</i> , 2021, 162, .	2.8	5
519	Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. <i>ACS Synthetic Biology</i> , 2021, 10, 2087-2095.	3.8	14
520	Clinical Perspectives of Single-Cell RNA Sequencing. <i>Biomolecules</i> , 2021, 11, 1161.	4.0	11
521	Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2066-2072.	2.3	6
522	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	2.0	16
523	Engineering stromal heterogeneity in cancer. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113817.	13.7	7
524	Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 695325.	3.7	27

#	ARTICLE	IF	CITATIONS
525	Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1122-1135.	7.3	47
526	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 851-863.	4.2	6
527	Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 651634.	4.8	47
528	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
529	Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy. <i>Rheumatology and Therapy</i> , 2021, 8, 1651-1659.	2.3	1
530	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. <i>Frontiers in Genetics</i> , 2021, 12, 723670.	2.3	9
531	Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. <i>Biomaterials</i> , 2021, 276, 121058.	11.4	13
532	Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1159-1173.	2.8	7
533	Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. <i>Biomedicines</i> , 2021, 9, 1277.	3.2	38
534	Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 730320.	4.8	39
535	An Integrative Pan-Cancer Analysis of the Prognostic and Immunological Role of Casein Kinase 2 Alpha Protein 1 (CSNK2A1) in Human Cancers: A Study Based on Bioinformatics and Immunohistochemical Analysis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6215-6232.	1.8	5
536	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	1.8	2
537	CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. <i>Oncogene</i> , 2021, 40, 6223-6234.	5.9	42
538	Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. <i>Open Research Europe</i> , 0, 1, 107.	2.0	1
539	Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	1.3	9
540	Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. <i>Radiology</i> , 2021, 301, 602-609.	7.3	22
541	Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10009.	4.1	14
542	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0

#	ARTICLE	IF	CITATIONS
543	Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell Chemical Biology, 2021, 28, 1258-1270.e13.	5.2	21
544	Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients. Biomolecules, 2021, 11, 1425.	4.0	12
545	PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends in Molecular Medicine, 2021, 27, 868-881.	6.7	30
546	Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunological Investigations, 2022, 51, 1498-1514.	2.0	8
547	Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. Seminars in Cancer Biology, 2021, 74, 24-44.	9.6	34
548	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. International Immunopharmacology, 2021, 98, 107876.	3.8	15
549	AXTEX-4D: A Three-Dimensional Ex Vivo Platform for Preclinical Investigations of Immunotherapy Agents. Assay and Drug Development Technologies, 2021, 19, 361-372.	1.2	3
550	The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Computational and Structural Biotechnology Journal, 2021, 19, 5428-5442.	4.1	5
551	MSI testing. Der Pathologe, 2021, 42, 110-118.	1.6	9
552	Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses. Molecular Therapy - Oncolytics, 2021, 22, 399-409.	4.4	2
553	Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol. BMJ Open, 2021, 11, e048141.	1.9	2
554	A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open, 2021, 6, 100272.	4.5	34
555	Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer. Life Sciences, 2021, 282, 119848.	4.3	8
556	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 434-446.	1.9	16
557	Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). Journal of Medicinal Chemistry, 2021, 64, 14757-14772.	6.4	13
558	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. European Journal of Cancer, 2021, 156, 46-59.	2.8	16
559	Avoiding immunogenic drugs is key to preserve renal function in patients receiving immune checkpoint inhibitors: Lessons learned from three illustrative cases. Journal of Onco-Nephrology, 0, , 239936932110485.	0.6	1
560	Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. International Immunopharmacology, 2021, 99, 107935.	3.8	19

#	ARTICLE	IF	CITATIONS
561	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. <i>European Journal of Pharmacology</i> , 2021, 909, 174404.	3.5	18
562	Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay. <i>Journal of Immunological Methods</i> , 2021, 498, 113134.	1.4	1
563	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	7.4	29
564	Discovery of 4-aminoquinolines as highly selective TGF β 1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113763.	5.5	1
565	Immune checkpoint inhibitors: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 335-344.	1.6	5
566	Management of Advanced Disease in NSCLC. , 2022, , 912-920.		0
567	Targeted photodynamic immunotherapy. , 2022, , 463-481.		1
568	Stromal modulation strategies to improve immunotherapy response in cancer. , 2022, , 241-291.		0
569	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
570	Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder cancer. <i>Gene</i> , 2022, 808, 145966.	2.2	1
571	Delivery strategies for immune checkpoint blockade. , 2022, , 1-29.		0
572	Polymeric scaffolds for antitumor immune cell priming. , 2022, , 63-95.		2
573	Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. <i>Scientific Reports</i> , 2021, 11, 1794.	3.3	3
574	Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. <i>Cancers</i> , 2021, 13, 288.	3.7	12
575	Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma. <i>Functional and Integrative Genomics</i> , 2021, 21, 125-138.	3.5	5
576	A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. <i>Theranostics</i> , 2021, 11, 6936-6949.	10.0	16
577	The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment. <i>Nanoscale Advances</i> , 2021, 3, 4961-4972.	4.6	15
578	Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. <i>Chemical Communications</i> , 2021, 57, 367-370.	4.1	20

#	ARTICLE	IF	CITATIONS
579	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies, 2021, 20, 153473542199007.	2.0	25
580	Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells <i>in vitro</i> . Gut Microbes, 2021, 13, 1-20.	9.8	9
581	Germline Genetics in Cancer: The New Frontier. , 2021, , 379-385.		0
582	Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	8
583	Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines, 2021, 9, 64.	4.4	11
584	Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists. Journal of Medicinal Chemistry, 2021, 64, 1649-1669.	6.4	21
585	Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions. Small, 2021, 17, e2004282.	10.0	30
586	TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. Journal of Leukocyte Biology, 2020, 107, 981-991.	3.3	22
587	Bioinformatics for Cancer Immunotherapy. Methods in Molecular Biology, 2020, 2120, 1-9.	0.9	22
588	CCL22 Signaling in the Tumor Environment. Advances in Experimental Medicine and Biology, 2020, 1231, 79-96.	1.6	30
589	CAR T Cell Therapy Progress and Challenges for Solid Tumors. Cancer Treatment and Research, 2020, 180, 297-326.	0.5	23
590	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecologic Oncology, 2020, 158, 167-177.	1.4	20
591	Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene, 2020, 39, 2835-2843.	5.9	15
592	Translational approaches to treating dynamical diseases through <i>in silico</i> clinical trials. Chaos, 2020, 30, 123128.	2.5	21
593	Photothermal therapies to improve immune checkpoint blockade for cancer. International Journal of Hyperthermia, 2020, 37, 34-49.	2.5	23
594	The current landscape of single-cell transcriptomics for cancer immunotherapy. Journal of Experimental Medicine, 2021, 218, .	8.5	35
595	Innovations in targeted therapies for triple negative breast cancer. Current Opinion in Obstetrics and Gynecology, 2021, 33, 34-47.	2.0	4
596	Operative Trauma and Blood Loss – Impact on Tumor Growth and Recurrence. Shock, 2021, 55, 455-464.	2.1	13

#	ARTICLE	IF	CITATIONS
597	Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1). Acta Crystallographica Section F, Structural Biology Communications, 2021, 77, 22-28.	0.8	6
598	Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2021, 53, 374-382.	3.7	54
599	Targeting DNA binding proteins for cancer therapy. Cancer Science, 2020, 111, 1058-1064.	3.9	17
600	Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. , 2020, 8, e001513.		17
601	Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. , 2020, 8, e001532.		38
602	Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight, 2020, 5, .	5.0	11
603	Cancer immunotherapy needs to learn how to stick to its guns. Journal of Clinical Investigation, 2019, 129, 5089-5091.	8.2	2
604	BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology, 2020, 4, 1393-1402.	3.0	52
605	New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000Research, 2019, 8, 1202.	1.6	3
606	Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. Gastroenterology Research, 2020, 13, 227-232.	1.3	7
607	Suicide among cancer patients: adolescents and young adult (AYA) versus all-age patients. Annals of Translational Medicine, 2019, 7, 658-658.	1.7	14
608	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	1.9	10
609	Current Progresses of Functional Nanomaterials for Imaging Diagnosis and Treatment of Melanoma. Current Topics in Medicinal Chemistry, 2019, 19, 2494-2506.	2.1	6
610	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.7	8
611	Oncolytic virotherapy: new weapon for breast cancer treatment. Ecancermedicalscience, 2020, 14, 1149.	1.1	12
612	Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Frontiers in Veterinary Science, 2021, 8, 621758.	2.2	6
613	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17.	2.5	14
614	The Proteomic Landscape of Resting and Activated CD4+ T Cells Reveal Insights into Cell Differentiation and Function. International Journal of Molecular Sciences, 2021, 22, 275.	4.1	9

#	ARTICLE	IF	CITATIONS
615	Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review). International Journal of Molecular Medicine, 2020, 47, 444-454.	4.0	16
616	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). International Journal of Oncology, 2020, 58, 145-157.	3.3	55
617	Prognostic value of immune cell infiltration in bladder cancer: A gene expression-based study. Oncology Letters, 2020, 20, 1677-1684.	1.8	6
618	Interferon- γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. Oncology Letters, 2020, 20, 2161-2168.	1.8	28
619	Early response of bone metastases can predict tumor response in patients with non-small-cell lung cancer with bone metastases in the treatment with nivolumab. Oncology Letters, 2020, 20, 2977-2986.	1.8	11
620	Immune checkpoint inhibitors in the driver's seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer. Journal of Current Oncology, 2019, 2, 43.	0.2	1
621	Molecular modulation of autophagy: New venture to target resistant cancer stem cells. World Journal of Stem Cells, 2020, 12, 303-322.	2.8	19
622	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 700-708.	4.9	19
623	Sex-Based Differences in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1329, 499-533.	1.6	3
624	Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology, 2022, 3, 140-169.	4.1	5
625	Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 53-63.	4.9	6
626	Molecular Signature Expands the Landscape of Driver Negative Thyroid Cancers. Cancers, 2021, 13, 5184.	3.7	0
627	Vaccines for Non-Viral Cancer Prevention. International Journal of Molecular Sciences, 2021, 22, 10900.	4.1	4
628	Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer. Frontiers in Medicine, 2021, 8, 715250.	2.6	8
629	Nanoparticle-Mediated <i>In Situ</i> Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy. ACS Nano, 2021, 15, 17549-17564.	14.6	16
630	Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC Cancer, 2021, 21, 1134.	2.6	7
631	The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review. Frontiers in Pharmacology, 2021, 12, 737674.	3.5	7
632	MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer. Current Issues in Molecular Biology, 2021, 43, 1529-1547.	2.4	5

#	ARTICLE	IF	CITATIONS
633	A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis. <i>Epileptic Disorders</i> , 2021, 23, 733-738.	1.3	1
634	Supramolecular peptide nanostructures: Self-assembly and biomedical applications. <i>Giant</i> , 2022, 9, 100082.	5.1	15
635	Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methyladenosine-Related LncRNAs. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 715764.	3.5	4
636	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	3.7	2
637	PD~L1 immunostaining: what pathologists need to know. <i>Diagnostic Pathology</i> , 2021, 16, 94.	2.0	39
638	Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 742489.	2.6	2
639	Anti~PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. <i>Clinical Cancer Research</i> , 2022, 28, 215-226.	7.0	5
640	Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. <i>Molecular Biology Reports</i> , 2021, 48, 8075-8095.	2.3	40
641	Construction of a Ferroptosis-Related Gene Signature for Predicting Survival and Immune Microenvironment in Melanoma Patients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6423-6438.	1.8	15
642	Immunological and prognostic significance of CBX2 expression in hepatocellular carcinoma. <i>World Chinese Journal of Digestology</i> , 2021, 29, 1118-1129.	0.1	0
643	Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 721181.	3.5	5
644	Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. <i>Molecular Cancer</i> , 2021, 20, 131.	19.2	702
645	A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. <i>Immunology Letters</i> , 2021, 240, 137-148.	2.5	4
646	Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2021, 101, 108242.	3.8	5
651	Immunotherapy of Gastric and Esophageal Cancers. , 2020, , 213-240.		0
652	Gene expression in peripheral blood cells for differentiation of active and latent tuberculosis infection in children and adolescents. <i>Tuberculosis and Lung Diseases</i> , 2020, 97, 28-32.	0.7	0
654	Preclinical imaging for targeting cancer immune evasion. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 186-193.	0.7	1
655	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. <i>Cureus</i> , 2020, 12, e8093.	0.5	7

#	ARTICLE	IF	CITATIONS
656	Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma. PeerJ, 2020, 8, e9362.	2.0	3
657	Using the TCGA Database to Predict and Analyze Tumor Microenvironment Genes Related to Poor Prognosis of Colon Cancer. Medical Science Monitor, 2020, 26, e923707.	1.1	2
658	RANBP9 as potential therapeutic target in non-small cell lung cancer. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	1
659	Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Research Europe, 0, 1, 107.	2.0	1
660	Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma. Cureus, 2021, 13, e19110.	0.5	1
661	Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. Kidney Cancer, 2021, 5, 167-179.	0.4	1
662	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer: Targets and Therapy, 2021, Volume 12, 123-131.	2.7	4
663	Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncology, 2021, 123, 105587.	1.5	2
665	Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. Methods in Molecular Biology, 2020, 2184, 233-263.	0.9	1
666	Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma. Minerva Medica, 2020, 111, 589-600.	0.9	0
667	An Integrative Analysis Reveals the Potential Mechanism between Herbal Medicine Yinchen and Immunoregulation in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-10.	1.9	6
668	Immune Cell Therapy Against Gastrointestinal Tract Cancers. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 61-77.	0.2	0
669	BET mechanisms in cancer. , 2020, , 101-142.		0
670	Therapeutic Vaccines for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 113-158.	0.2	1
671	Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Drug Delivery, 2021, 28, 2313-2328.	5.7	5
672	Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	6.4	35
673	Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. Frontiers in Chemistry, 2021, 9, 766107.	3.6	7
674	Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	3.7	3

#	ARTICLE	IF	CITATIONS
676	Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 19.	1.8	8
678	Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. <i>Oncotarget</i> , 2020, 11, 3972-3983.	1.8	2
680	CD122-targeted interleukin-2 and \pm PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. <i>Onc Immunology</i> , 2021, 10, 2006529.	4.6	1
681	Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100489.	1.7	2
682	Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation. , 2021, , 277-304.		0
683	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751209.	2.8	10
684	HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy. <i>Scientific Reports</i> , 2021, 11, 22158.	3.3	6
685	Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases. <i>Frontiers in Genetics</i> , 2021, 12, 785153.	2.3	28
686	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. <i>Cancers</i> , 2021, 13, 5999.	3.7	6
687	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 762478.	3.7	8
688	Anticancer natural products targeting immune checkpoint protein network. <i>Seminars in Cancer Biology</i> , 2022, 86, 1008-1032.	9.6	8
689	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <i>Cell Communication and Signaling</i> , 2021, 19, 117.	6.5	25
690	Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression. <i>Acta Neuropathologica Communications</i> , 2021, 9, 183.	5.2	21
691	Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 785185.	2.3	13
692	A Novel Nine-Gene Signature Associated With Immune Infiltration for Predicting Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 730732.	2.3	2
693	C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models. <i>Cancer Immunology Research</i> , 2022, 10, 245-258.	3.4	7
694	Penpulimab: First Approval. <i>Drugs</i> , 2021, 81, 2159-2166.	10.9	17
695	Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1725-1740.	2.0	5

#	ARTICLE	IF	CITATIONS
696	The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumoursâ€”A real-world multicentric study from India. <i>International Journal of Cancer</i> , 2021, , .	5.1	5
697	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
698	Sarcopeniaâ€™s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5329.	2.4	8
699	A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 24866-24881.	3.1	4
700	Impact of immune cells on the hallmarks of cancer: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103541.	4.4	27
701	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. <i>International Immunopharmacology</i> , 2021, 101, 108337.	3.8	3
702	Genetic Association and Mendelian Randomization for Hypothyroidism Highlight Immune Molecular Mechanisms. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
703	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
704	Comprehensive genomic profiling and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the stomach and parotid gland. <i>Annals of Translational Medicine</i> , 2022, 10, 13-13.	1.7	0
705	Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. <i>Onc Immunology</i> , 2021, 10, .	4.6	14
706	Immunotherapy in skin cancers - A narrative review. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0
707	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. <i>Cancers</i> , 2022, 14, 294.	3.7	24
708	Cancer immunomodulation using bispecific aptamers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 894-915.	5.1	20
709	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112558.	5.6	10
710	BACH1 as a potential target for immunotherapy in glioblastomas. <i>International Immunopharmacology</i> , 2022, 103, 108451.	3.8	11
711	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	5.6	38
712	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. <i>International Immunopharmacology</i> , 2022, 103, 108484.	3.8	2
713	Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool. <i>JPRAS Open</i> , 2022, 31, 114-122.	0.9	1

#	ARTICLE	IF	CITATIONS
714	Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features. Journal of Nippon Medical School, 2022, 89, 128-138.	0.9	4
715	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320.	4.1	43
716	Eosinophils and melanoma: Implications for immunotherapy. Pigment Cell and Melanoma Research, 2022, 35, 192-202.	3.3	5
717	Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients. Frontiers in Immunology, 2021, 12, 797407.	4.8	9
718	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	3.3	7
719	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	16
720	Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma. EMBO Reports, 2022, 23, e54127.	4.5	6
721	Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma. International Journal of General Medicine, 2022, Volume 15, 913-926.	1.8	2
722	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 806963.	2.8	14
723	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022, 22, 2.	4.1	83
724	The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer. Experimental and Molecular Medicine, 2022, 54, 12-22.	7.7	12
725	Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence. Cancers, 2022, 14, 213.	3.7	0
726	mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers. SSRN Electronic Journal, 0, , .	0.4	0
727	Systematic analysis of the role of SLC52A2 in multiple human cancers. Cancer Cell International, 2022, 22, 8.	4.1	7
728	Emerging strategies for biomaterial-assisted cancer immunotherapy. Korean Journal of Chemical Engineering, 2022, 39, 227-240.	2.7	1
729	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 2022, 28, 368-377.	7.0	40
730	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. Nanotheranostics, 2022, 6, 243-255.	5.2	17
731	Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma. PeerJ, 2022, 10, e12646.	2.0	1

#	ARTICLE	IF	CITATIONS
733	Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy's existing prospects and challenges in drug targets. <i>Current Drug Targets</i> , 2022, 23, .	2.1	2
734	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. <i>Hepatology</i> , 2022, 76, 630-645.	7.3	13
735	Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 437-449.	1.8	2
736	Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). <i>International Journal of Oncology</i> , 2022, 60, .	3.3	7
737	PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers. <i>Biomedicines</i> , 2022, 10, 299.	3.2	3
738	Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. <i>Molecular Cancer</i> , 2022, 21, 31.	19.2	42
739	The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	2
740	Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-11.	4.0	14
741	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 811200.	4.8	7
742	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103596.	4.4	76
743	Bilateral diffuse uveal melanocytic proliferation: Report of a novel optical coherence tomography finding and clinical response to plasmapheresis. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 25, 101349.	0.7	3
744	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
745	The Efficacy and Safety of PD-1/PD-L1 Immunosuppressive Agents in Advanced Esophageal Cancer: A Meta-Analysis. <i>Advances in Clinical Medicine</i> , 2022, 12, 828-837.	0.0	0
746	Antibody- Incorporated Nanomedicines for Cancer Therapy. <i>Advanced Materials</i> , 2022, 34, e2109210.	21.0	32
747	Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. <i>Head and Neck</i> , 2022, 44, 1237-1245.	2.0	20
748	Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 542-565.	9.6	51
749	Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. <i>ESMO Open</i> , 2022, 7, 100396.	4.5	9
750	Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 820135.	2.3	6

#	ARTICLE	IF	CITATIONS
751	Immunotherapies for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 571-591.	2.8	29
752	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. <i>Journal of Cancer</i> , 2022, 13, 1933-1944.	2.5	6
753	The role of DNA mismatch repair in immunotherapy of human cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2821-2832.	6.4	20
754	Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 458-468.	2.5	5
755	PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β -catenin signaling pathways. <i>Scientific Reports</i> , 2022, 12, 3053.	3.3	23
756	RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 66.	8.6	18
757	New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. <i>Cells</i> , 2022, 11, 768.	4.1	14
758	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	3.2	9
759	An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets. <i>Life</i> , 2022, 12, 323.	2.4	4
760	Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 3079.	3.3	6
761	Histone Deacetylases as Modulators of the Crosstalk Between Skeletal Muscle and Other Organs. <i>Frontiers in Physiology</i> , 2022, 13, 706003.	2.8	8
762	CD84 is a Suppressor of T and B Cell Activation during Mycobacterium tuberculosis Pathogenesis. <i>Microbiology Spectrum</i> , 2022, 10, e0155721.	3.0	3
763	Mitochondrial Fus1/Tusc2 and cellular Ca ²⁺ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. <i>Cancer Gene Therapy</i> , 2022, 29, 1307-1320.	4.6	4
764	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. <i>Seminars in Cancer Biology</i> , 2022, 86, 909-922.	9.6	26
765	Genome-wide identification and analysis of prognostic features in human cancers. <i>Cell Reports</i> , 2022, 38, 110569.	6.4	48
766	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
767	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	4.8	13
768	Comprehensive Analysis Identified Mutation-Gene Signature Impacts the Prognosis Through Immune Function in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 748557.	2.8	1

#	ARTICLE	IF	CITATIONS
769	Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration, 2022, 2, .	11.0	68
770	Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. Clinical and Experimental Immunology, 2022, 209, 64-71.	2.6	5
771	Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Cancer Biology and Therapy, 2022, 23, 104-111.	3.4	19
772	Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach. Journal of Clinical Medicine, 2022, 11, 1659.	2.4	2
773	Comprehensive Analysis of the Immune and Prognostic Implication of TRIM8 in Breast Cancer. Frontiers in Genetics, 2022, 13, 835540.	2.3	1
774	CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. Clinical and Experimental Immunology, 2022, 208, 220-232.	2.6	6
775	Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Seminars in Cancer Biology, 2022, 86, 137-150.	9.6	70
776	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
777	Identification and Verification of the Ferroptosis- and Pyroptosis-Associated Prognostic Signature for low-grade Glioma. Bosnian Journal of Basic Medical Sciences, 2022, , .	1.0	14
778	Recent advancements in lipidâ€mRNA nanoparticles as a treatment option for cancer immunotherapy. Journal of Pharmaceutical Investigation, 2022, 52, 415-426.	5.3	21
779	Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine. Molecular Therapy - Oncolytics, 2022, 24, 650-662.	4.4	2
780	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. Journal of Clinical Pharmacology, 2022, 62, 1059-1078.	2.0	0
781	Targeting CAFs to overcome anticancer therapeutic resistance. Trends in Cancer, 2022, 8, 527-555.	7.4	68
782	Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes. Frontiers in Oncology, 2022, 12, 852803.	2.8	10
783	Development of Peptide-Based Vaccines for Cancer. Journal of Oncology, 2022, 2022, 1-17.	1.3	32
784	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Molecular Biomedicine, 2022, 3, 8.	4.4	38
785	Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data. Frontiers in Oncology, 2022, 12, 824511.	2.8	9
786	Kanser imm�¼noterapisinde g�¼ncel yakla��mlar ve imm�¼noterapinin s�¼n��rlay��c�� etkilerine genel bak���. Turkish Journal of Clinics and Laboratory, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
787	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study. <i>Cancer Medicine</i> , 2022, 11, 3074-3083.	2.8	16
788	Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. <i>Cell Communication and Signaling</i> , 2022, 20, 49.	6.5	71
789	A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. <i>BMC Cancer</i> , 2022, 22, 365.	2.6	11
790	The Role of NcRNAs to Regulate Immune Checkpoints in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 853480.	4.8	12
791	Self-assembling peptides-based nano-cargos for targeted chemotherapy and immunotherapy of tumors: recent developments, challenges, and future perspectives. <i>Drug Delivery</i> , 2022, 29, 1184-1200.	5.7	17
792	Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2691-2700.	4.2	5
793	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	6.5	109
794	A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect <i>vs.</i> COVID-19 related immunization complications. <i>International Journal of Neuroscience</i> , 2022, , 1-4.	1.6	7
795	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. <i>Clinical and Experimental Medicine</i> , 2023, 23, 313-331.	3.6	21
796	Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 801924.	2.8	1
797	Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. <i>Frontiers in Immunology</i> , 2022, 13, 840207.	4.8	7
798	High Expression of CSF-1R Predicts Poor Prognosis and CSF-1R ^{high} Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 850767.	2.8	6
799	Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities. <i>International Journal of Biological Macromolecules</i> , 2022, 207, 1022-1037.	7.5	9
800	QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 173, 106171.	4.0	6
801	Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 599-612.	2.4	1
802	Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. <i>Tumori</i> , 2021, , 030089162110639.	1.1	4
803	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. <i>Cancers</i> , 2022, 14, 52.	3.7	11
804	Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. <i>Life</i> , 2021, 11, 1400.	2.4	1

#	ARTICLE	IF	CITATIONS
805	A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer. <i>Vaccines</i> , 2021, 9, 1510.	4.4	3
806	Moving forward in the treatment of cholangiocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1939-1955.	2.0	4
807	The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. <i>Translational Lung Cancer Research</i> , 2021, 10, 4600-4616.	2.8	5
808	Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 124.	2.4	9
809	CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. <i>Oncology Letters</i> , 2021, 23, 51.	1.8	9
810	A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10467-10481.	1.8	2
811	Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	1.3	0
812	PMEPA1 Serves as a Prognostic Biomarker and Correlates with Immune Infiltrates in Cervical Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	2.2	1
813	Identification of a pyroptosis-related prognostic signature in breast cancer. <i>BMC Cancer</i> , 2022, 22, 429.	2.6	17
814	Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. <i>Cancer Medicine</i> , 2022, 11, 3886-3901.	2.8	9
815	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2022, 13, 774440.	3.5	5
816	Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 882531.	2.8	13
817	The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. <i>Investigational New Drugs</i> , 2022, 40, 810-817.	2.6	5
818	Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. <i>Cell Death and Disease</i> , 2022, 13, 378.	6.3	37
836	Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. <i>EXCLI Journal</i> , 2022, 21, 250-268.	0.7	10
837	Escherichia coli Mimetic Gold Nanorod-Mediated Photo- and Immunotherapy for Treating Cancer and Its Metastasis. <i>ACS Nano</i> , 2022, 16, 8472-8483.	14.6	26
838	The Challenging Management of Cancer: An Immunonephrologist's Perspective. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 114-120.	2.0	2
839	Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).. <i>Iranian Journal of Basic Medical Sciences</i> , 2021, 24, 1264-1271.	1.0	0

#	ARTICLE	IF	CITATIONS
842	Development of Cancer Immunotherapies. Cancer Treatment and Research, 2022, 183, 1-48.	0.5	4
843	Intestinal stents: Structure, functionalization and advanced engineering innovation. , 2022, 137, 212810.		4
844	A Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy. Frontiers in Molecular Biosciences, 2022, 9, 776808.	3.5	10
845	CHSY3 can be a Poor Prognostic Biomarker and Mediates Immune Evasion in Stomach Adenocarcinoma. Frontiers in Genetics, 2022, 13, 876588.	2.3	0
846	Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy. World Journal of Oncology, 2022, 13, 49-52.	1.5	8
847	A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma. Journal of Immunology Research, 2022, 2022, 1-13.	2.2	5
848	A prognostic model for oral squamous cell carcinoma using 7 genes related to tumor mutational burden. BMC Oral Health, 2022, 22, 152.	2.3	5
849	Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123483119.	7.1	0
850	From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade. Frontiers in Oncology, 2022, 12, .	2.8	0
851	The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development. Advanced Drug Delivery Reviews, 2022, 186, 114316.	13.7	17
852	Clinical applications of plasma proteomics and peptidomics: Towards precision medicine. Proteomics - Clinical Applications, 2022, 16, e2100097.	1.6	20
853	Characterizing the landscape of cervical squamous cell carcinoma immune microenvironment by integrating the single-cell transcriptomics and RNA-seq. Immunity, Inflammation and Disease, 2022, 10, .	2.7	4
854	An Autoimmune Encephalitis Case Associated with Pembrolizumab Use. Journal of the Korean Neurological Association, 2022, 40, 137-140.	0.1	0
855	Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1278-1298.	5.2	36
856	Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors. Siberian Journal of Oncology, 2022, 21, 109-117.	0.3	0
857	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3878-3891.	6.4	3
860	Update in TIGIT Immune-Checkpoint Role in Cancer. Frontiers in Oncology, 2022, 12, .	2.8	19
861	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. Scientific Reports, 2022, 12, 8230.	3.3	9

#	ARTICLE	IF	CITATIONS
862	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets, 2022, 26, 405-425.	3.4	3
863	Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm. Journal of the American Chemical Society, 2022, 144, 10006-10016.	13.7	9
864	Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics. Analytical Chemistry, 2022, 94, 7970-7980.	6.5	5
865	Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 54-74.	4.3	3
866	Preliminary Assessment of Cardiotoxicity in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
867	Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. Cancers, 2022, 14, 2590.	3.7	17
868	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. Journal of Translational Medicine, 2022, 20, .	4.4	9
869	Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Cancers, 2022, 14, 2545.	3.7	37
870	Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Advanced Drug Delivery Reviews, 2022, 187, 114365.	13.7	30
871	Associations of different immune checkpoints-expressing CD4+ Treg/ T cell subsets with disease-free survival in colorectal cancer patients. BMC Cancer, 2022, 22, .	2.6	7
872	Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Frontiers of Medicine, 2022, 16, 307-321.	3.4	6
873	Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis. Genes, 2022, 13, 1017.	2.4	2
874	Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC. Lung Cancer, 2022, , .	2.0	5
875	High-Dose Vitamin C for Cancer Therapy. Pharmaceuticals, 2022, 15, 711.	3.8	23
876	IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. Frontiers in Immunology, 0, 13, .	4.8	10
877	High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer. Frontiers in Genetics, 0, 13, .	2.3	2
878	Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers. Cancers, 2022, 14, 3104.	3.7	1
879	Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer. International Journal of Molecular Sciences, 2022, 23, 6473.	4.1	2

#	ARTICLE	IF	CITATIONS
880	High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. <i>Biomedicines</i> , 2022, 10, 1405.	3.2	1
881	The Prognostic and Immunotherapeutic Significance of AHS1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
882	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2022, 151, 1626-1639.	5.1	8
883	Emerging trends in immunotoxin targeting cancer stem cells. <i>Toxicology in Vitro</i> , 2022, 83, 105417.	2.4	8
884	Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	134
885	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
886	Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 1039.	2.5	3
887	Intratumoral injection of schwannoma with attenuated <i>Salmonella typhimurium</i> induces antitumor immunity and controls tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	12
888	A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
889	Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
890	Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
891	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	2.4	6
892	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3440.	3.7	1
893	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. <i>Discover Oncology</i> , 2022, 13, .	2.1	3
894	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	5
895	EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	6
896	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
897	Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	19

#	ARTICLE	IF	CITATIONS
898	Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 1282.	2.4	2
899	Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system. <i>Biomaterials</i> , 2022, 288, 121677.	11.4	4
900	Extracellular Vesicles for Cancer Immunotherapy: Biomarkers and Beyond. <i>Physiology</i> , 0, , .	10.0	0
901	Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1195.	4.4	11
902	Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	1
903	Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. <i>Immunologic Research</i> , 2022, 70, 725-741.	2.9	13
904	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	44
905	Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	20
906	Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1 β and PD-1 inhibition. <i>Future Oncology</i> , 2022, 18, 3085-3100.	2.4	9
907	Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine. <i>Investigational New Drugs</i> , 2022, 40, 1173-1184.	2.6	6
908	Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. <i>Clinical and Translational Oncology</i> , 2022, 24, 2255-2271.	2.4	6
909	Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
910	Low-Intensity Focused Ultrasound Produces Immune Response in Pancreatic Cancer. <i>Ultrasound in Medicine and Biology</i> , 2022, 48, 2344-2353.	1.5	7
911	Echocardiographic and Cardiac MRI Comparison of Longitudinal Strain and Strain Rate in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Personalized Medicine</i> , 2022, 12, 1332.	2.5	1
912	Genetic association and Mendelian randomization for hypothyroidism highlight immune molecular mechanisms. <i>IScience</i> , 2022, 25, 104992.	4.1	7
913	The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 4523.	2.4	7
915	Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	89
916	Microenvironment in Oral Potentially Malignant Disorders: Multi-Dimensional Characteristics and Mechanisms of Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8940.	4.1	6

#	ARTICLE	IF	CITATIONS
917	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. <i>Cancers</i> , 2022, 14, 3779.	3.7	18
918	Construction of a prognostic risk model based on apoptosis-related genes to assess tumor immune microenvironment and predict prognosis in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	3
919	Molecular Diagnostics and Immunological Markers of Neurodegenerative Disorders. , 2022, , 125-142.		0
920	The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3830.	3.7	5
921	Nanoscale Zeolitic Imidazolate Framework (ZIF)â€”8 in Cancer Theranostics: Current Challenges and Prospects. <i>Cancers</i> , 2022, 14, 3935.	3.7	28
922	Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. <i>Medicina (Lithuania)</i> , 2022, 58, 1069.	2.0	19
923	Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
924	Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	9
925	The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. <i>Disease Markers</i> , 2022, 2022, 1-8.	1.3	1
926	The epiphany derived from T-cellâ€”inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
927	Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
928	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3833.	3.7	4
929	Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	1
930	SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. <i>Aging</i> , 2022, 14, 6316-6337.	3.1	6
931	Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3828.	3.7	3
933	Treatment of gastric carcinoma with lymphoid stroma by immunotherapy: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 8962-8967.	0.8	2
934	Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128947.	2.2	6
935	Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma. <i>Cancer Discovery</i> , 2022, 12, 2820-2837.	9.4	29

#	ARTICLE	IF	CITATIONS
936	Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
937	Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. <i>Pathology Research and Practice</i> , 2022, 238, 154110.	2.3	1
938	Integrative pan-cancer analysis indicates the prognostic importance of long noncoding RNA SNHG17 in human cancers. <i>Pathology Research and Practice</i> , 2022, 238, 154140.	2.3	3
939	Landscape of exons in gastric cancer. <i>EBioMedicine</i> , 2022, 84, 104272.	6.1	1
940	Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 3-13.	4.4	14
941	Discovery of 3,4-Dihydropyrimido[4,5- <i>d</i>]Pyrimidin-2(1 <i>H</i>)-One and 3,4-Dihydropyrido[2,3- <i>d</i>]Pyrimidin-2(1 <i>H</i>)-One Derivatives as Novel ENPP1 Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
942	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5150-5161.	4.1	5
943	Clinical Approaches in Targeting ROS-Induced Cancer. , 2022, , 2599-2614.		0
944	PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer. <i>Nanoscale</i> , 2022, 14, 14014-14022.	5.6	1
945	Pulmonology (Lung). , 2022, , 275-299.		1
946	Medical use of cell-penetrating peptides: how far have they come?. , 2022, , 235-254.		0
947	Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	1.3	2
948	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2022, 14, 4246.	3.7	4
949	<sc>COL3A1</sc>: Potential prognostic predictor for head and neck cancer based on immuneâ€microenvironment alternative splicing. <i>Cancer Medicine</i> , 2023, 12, 4882-4894.	2.8	7
950	Gut microbiota shed new light on the management of <sc>immuneâ€related</sc> adverse events. <i>Thoracic Cancer</i> , 2022, 13, 2681-2691.	1.9	10
951	Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	4
952	Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma. <i>Aging</i> , 2022, 14, 6917-6935.	3.1	4
953	Boosting the Immune Responseâ€Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	4.1	3

#	ARTICLE	IF	CITATIONS
954	Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database. <i>Metabolism: Clinical and Experimental</i> , 2023, 138, 155311.	3.4	4
955	Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma. <i>Nature Communications</i> , 2022, 13, .	12.8	16
956	Plasmid DNA for Therapeutic Applications in Cancer. <i>Pharmaceutics</i> , 2022, 14, 1861.	4.5	13
957	Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
959	The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
960	Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	14
961	The pro-tumorigenic responses in metastatic niches: an immunological perspective. <i>Clinical and Translational Oncology</i> , 2023, 25, 333-344.	2.4	3
963	Artificial Intelligence-Powered Whole-Slide Image Analyzer Reveals a Distinctive Distribution of Tumor-Infiltrating Lymphocytes in Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2022, 12, 2340.	2.6	3
964	Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	20
965	In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	12.8	15
967	Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression. <i>Angiogenesis</i> , 0, , .	7.2	2
968	Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
969	Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	1.1	1
970	S-acylthioalkyl ester (SATE)-based prodrugs of deoxyribose cyclic dinucleotides (dCDNs) as the STING agonist for antitumor immunotherapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114796.	5.5	11
971	The development of small-molecule inhibitors targeting HPK1. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114819.	5.5	12
972	AKT Isoforms as a Target in Cancer and Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 409-436.	1.1	0
973	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	2.5	6
974	Smart bio-encapsulation for immunotherapy. , 2022, , 75-90.		0

#	ARTICLE	IF	CITATIONS
975	Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. <i>Biomaterials Science</i> , 2022, 10, 6755-6767.	5.4	3
976	Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12641.	4.1	6
977	Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2023, 46, 43-55.	2.4	4
978	CXCL8 Up-Regulated LSECtin through AKT Signal and Correlates with the Immune Microenvironment Modulation in Colon Cancer. <i>Cancers</i> , 2022, 14, 5300.	3.7	4
979	Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. <i>Nature Communications</i> , 2022, 13, .	12.8	12
980	Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
981	Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
982	Cancer-associated inflammation: pathophysiology and clinical significance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2657-2672.	2.5	10
983	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	3.7	5
984	Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood. <i>Biomedicines</i> , 2022, 10, 2534.	3.2	1
985	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
986	Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. <i>Cancers</i> , 2022, 14, 5167.	3.7	5
987	MELK is a prognostic biomarker and correlated with immune infiltration in glioma. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
988	Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications. <i>Pharmaceutics</i> , 2022, 14, 2244.	4.5	4
989	Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	4.3	0
990	The influence of machine learning technologies in gut microbiome research and cancer studies - A review. <i>Life Sciences</i> , 2022, 311, 121118.	4.3	5
991	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. <i>Pharmaceutics</i> , 2022, 14, 2326.	4.5	2
992	<sc>MYC</sc> and therapy resistance in cancer: risks and opportunities. <i>Molecular Oncology</i> , 2022, 16, 3828-3854.	4.6	20

#	ARTICLE	IF	CITATIONS
993	The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges. Applied Sciences (Switzerland), 2022, 12, 10548.	2.5	0
994	Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. Critical Reviews in Oncology/Hematology, 2022, 180, 103863.	4.4	1
995	Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. International Journal of Molecular Sciences, 2022, 23, 13356.	4.1	3
996	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022.	2.5	4
997	Immunotherapy approaches for hematological cancers. IScience, 2022, 25, 105326.	4.1	9
998	The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. Cancer Letters, 2022, 551, 215947.	7.2	1
999	Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. Journal of Controlled Release, 2022, 352, 328-337.	9.9	4
1000	Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy. Biomaterials, 2022, 291, 121871.	11.4	23
1001	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	4.3	14
1002	TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC. Biochemistry and Biophysics Reports, 2022, 32, 101359.	1.3	1
1003	Unraveling the peripheral and local role of inflammatory cytokines in glioblastoma survival. Cytokine, 2023, 161, 156059.	3.2	3
1004	The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance. Cytokine, 2023, 161, 156081.	3.2	3
1005	The New T Cell Subset Opens a New Realm for Tumor Immunotherapy. Cell Transplantation, 2022, 31, 096368972211380.	2.5	1
1006	Immunotherapy as an emerging and promising tool against viral infections. , 2023, , 625-651.		0
1007	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences, 2022, 23, 13961.	4.1	10
1008	Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma. Frontiers in Immunology, 0, 13, .	4.8	6
1009	Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study. Scientific Reports, 2022, 12, .	3.3	7
1010	Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences, 2022, 23, 14121.	4.1	4

#	ARTICLE	IF	CITATIONS
1011	Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 5618.	3.7	2
1012	Emerging evidence of immunotherapy for colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 216-224.	2.4	4
1013	New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome. <i>Oncogematologiya</i> , 2022, 17, 106-117.	0.3	0
1014	Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4327-4347.	12.0	78
1015	Ginseng fermentation solution is associated with immune response in lung adenocarcinoma by modulating the differential expression of the m7G regulators. <i>Journal of Functional Foods</i> , 2022, 99, 105337.	3.4	0
1016	Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1017	Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers. <i>Cancers</i> , 2022, 14, 5663.	3.7	5
1018	Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. <i>Small</i> , 2023, 19, .	10.0	12
1019	A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma. <i>Translational Andrology and Urology</i> , 2021, .	1.4	0
1020	Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26.		0
1021	Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy. <i>Theranostics</i> , 2023, 13, 40-58.	10.0	6
1022	Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. <i>Seminars in Cancer Biology</i> , 2023, 88, 81-95.	9.6	11
1023	Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis. <i>Gene</i> , 2023, 856, 147132.	2.2	1
1024	Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	3.2	1
1025	The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations. <i>Cells</i> , 2022, 11, 3818.	4.1	6
1026	Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. <i>Vaccines</i> , 2022, 10, 2049.	4.4	0
1027	Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 98-104.	1.4	7
1028	Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. <i>Vaccines</i> , 2022, 10, 1993.	4.4	8

#	ARTICLE	IF	CITATIONS
1029	Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
1030	Analysis of Hepatic Adverse Event in Patients Treated with Immune Checkpoint Inhibitor. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2022, 39, 476-487.	0.1	0
1031	KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	27
1033	Baseline immune signature score of Tregs — HLA-DR+CD4+ T cells — PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1034	Adrenal Gland. , 2022, , 189-273.		0
1035	YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment. <i>Frontiers in Chemistry</i> , 0, 10, .	3.6	1
1036	Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment. <i>Scientific Reports</i> , 2022, 12, .	3.3	1
1037	A practical approach for PD-L1 evaluation in gastroesophageal cancer. <i>Pathologica</i> , 2023, 115, 57-70.	3.4	2
1038	Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. <i>Frontiers in Materials</i> , 0, 9, .	2.4	0
1039	The difficulty in translating the preclinical success of combined TGF β 2 and immune checkpoint inhibition to clinical trial. <i>EBioMedicine</i> , 2022, 86, 104380.	6.1	17
1040	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
1041	Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5497-5512.	2.5	11
1042	TGF β 2: A novel predictor and target for anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	22
1043	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	4.1	6
1044	Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
1045	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	4.1	3
1046	Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model. <i>Cancer Immunology Research</i> , 2023, 11, 217-227.	3.4	4
1048	Introduction on Personalized Immune-Oncology. , 2023, , 1-25.		0

#	ARTICLE	IF	CITATIONS
1049	Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1351-1364.	1.6	3
1050	Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy. <i>JACC: CardioOncology</i> , 2022, 4, 660-669.	4.0	7
1051	The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	4
1052	CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	1
1053	Systemic immune inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. <i>Immunotherapy</i> , 2022, 14, 1481-1496.	2.0	26
1054	Nanovaccines for cancer immunotherapy: Current knowledge and future perspectives. <i>Chinese Chemical Letters</i> , 2023, 34, 108098.	9.0	6
1055	Diverse effects of obesity on antitumor immunity and immunotherapy. <i>Trends in Molecular Medicine</i> , 2022, , .	6.7	2
1056	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <i>Cancers</i> , 2022, 14, 6145.	3.7	10
1057	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. <i>European Journal of Cell Biology</i> , 2023, 102, 151284.	3.6	8
1058	Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
1059	Integrative stemness characteristics associated with prognosis and the immune microenvironment in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	2.0	1
1061	Current Targeted Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1702.	4.1	22
1062	Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. <i>Oncologist</i> , 2023, 28, 440-448.	3.7	8
1063	The effect of Wnt/ β -catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. <i>Oncology Research</i> , 2022, 30, 99-116.	1.5	7
1064	Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1280.	4.1	5
1065	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	4.2	93
1066	Identification of cuproptosis related subtypes and construction of prognostic signature in gastric cancer. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	0
1067	A circadian rhythm-related gene signature for prognosis, invasion and immune microenvironment of breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0

#	ARTICLE	IF	CITATIONS
1068	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1069	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2023, 2023, 1-13.	1.3	0
1070	Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
1071	Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
1072	Biomaterial-Based In Situ Cancer Vaccines. <i>Advanced Materials</i> , 0, , .	21.0	13
1073	The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 84-90.	1.4	6
1074	Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. <i>PLoS ONE</i> , 2023, 18, e0280364.	2.5	2
1075	Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0
1076	Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse event. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2023, 2023, .	0.5	1
1077	CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. <i>PeerJ</i> , 0, 11, e14668.	2.0	0
1078	Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Cancer Policy</i> , 2023, 35, 100382.	1.4	1
1079	Modified method for differentiation of myeloid-derived suppressor cells in vitro enhances immunosuppressive ability via glutathione metabolism. <i>Biochemistry and Biophysics Reports</i> , 2023, 33, 101416.	1.3	1
1080	Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment. <i>Coordination Chemistry Reviews</i> , 2023, 480, 215027.	18.8	23
1081	Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide. <i>Pharmaceutics</i> , 2023, 15, 130.	4.5	1
1082	Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. <i>Biomedicines</i> , 2023, 11, 83.	3.2	3
1083	Cerebellar High-Grade Glioma: A Translationally Oriented Review of the Literature. <i>Cancers</i> , 2023, 15, 174.	3.7	1
1084	Improved cancer immunotherapy strategies by nanomedicine. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	6.1	7
1085	The Rise in Immunotherapy and Associated Ocular Toxicities. , 2022, , 337-347.		0

#	ARTICLE	IF	CITATIONS
1086	Immune Checkpoint Inhibitors and Optic Neuropathy: A Systematic Review. <i>Seminars in Ophthalmology</i> , 2023, 38, 547-558.	1.6	1
1087	<i>Infection and Immunity</i> , 2023, , 493-598.		1
1088	Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
1089	Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study. <i>Journal of Personalized Medicine</i> , 2023, 13, 206.	2.5	0
1090	Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2023, 2023, 1-22.	1.9	0
1091	Comprehensive Analysis of KCNJ14 Potassium Channel as a Biomarker for Cancer Progression and Development. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2049.	4.1	3
1092	Perspective Chapter: Impact of Tumor Metabolism on Immune Cells in the Tumor Microenvironment. , 0, , .		0
1093	<i>Immunotherapy for Breast Cancer</i> , 2023, , 1-30.		0
1094	Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. <i>Journal of Immunology Research</i> , 2023, 2023, 1-17.	2.2	3
1095	Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. <i>Current Opinion in Oncology</i> , 2023, 35, 94-99.	2.4	4
1096	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	4.3	6
1097	High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle. <i>Disease Markers</i> , 2023, 2023, 1-20.	1.3	4
1098	Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune-suppressive Cells with a Nanoparticulated Anti-inflammatory Drug. <i>Small</i> , 2023, 19, .	10.0	1
1099	An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311520.	1.9	17
1100	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	19.2	15
1101	Research Advances in Immunotherapy for Pancreatic Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 3457-3462.	0.0	0
1102	<i>Current Treatment Approaches to Breast Cancer</i> , 2023, , 23-51.		0
1103	The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas. <i>Cells</i> , 2023, 12, 755.	4.1	5

#	ARTICLE	IF	CITATIONS
1104	Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
1105	Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	2
1106	T Cell-Association of Carboxy-Terminal Dendrimers with Different Bound Numbers of Phenylalanine and Their Application to Drug Delivery. <i>Pharmaceutics</i> , 2023, 15, 888.	4.5	2
1107	PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	7.0	4
1108	Application of radiomics in lung immuno-oncology. <i>Precision Radiation Oncology</i> , 2023, 7, 128-136.	1.1	1
1109	ER stress modulates the immune regulatory ability in gut M2 cells of patients with ulcerative colitis. <i>IScience</i> , 2023, 26, 106498.	4.1	0
1110	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	3.8	2
1111	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	3.8	8
1112	In vitro models of breast cancer bone metastasis: analyzing drug resistance through the lens of the microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
1113	Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells. <i>International Immunopharmacology</i> , 2023, 118, 109988.	3.8	1
1114	Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114601.	5.6	2
1115	Mechano-modulation of T cells for cancer immunotherapy. <i>Biomaterials</i> , 2023, 297, 122101.	11.4	5
1116	Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. <i>Computers in Biology and Medicine</i> , 2023, 159, 106866.	7.0	0
1118	Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data. <i>Oncologie</i> , 2022, 24, 835-863.	0.7	5
1119	A Novel Tri-Functional Liposome Re-Educes "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	3
1120	Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	3
1121	Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2858.	4.1	9
1122	A Rare Case of Pembrolizumab-Associated Graves' Disease. <i>Cureus</i> , 2023, , .	0.5	1

#	ARTICLE	IF	CITATIONS
1124	Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer, 2023, 23, .	2.6	4
1125	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. Cell Death Discovery, 2023, 9, .	4.7	6
1126	The Genesâ€œStemnessâ€œSecretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints. International Journal of Molecular Sciences, 2023, 24, 3496.	4.1	0
1127	Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. Immuno-Oncology Technology, 2023, 17, 100374.	0.3	4
1128	Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6513-6526.	2.5	1
1129	Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines, 2023, 11, 528.	3.2	0
1130	<it>Salmonella typhimurium</it> may support cancer treatment: a review. Acta Biochimica Et Biophysica Sinica, 2023, 55, 331-342.	2.0	2
1131	Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment. Frontiers in Immunology, 0, 14, .	4.8	0
1132	Lessons learned from evolving frameworks in adult glioblastoma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 131-140.	1.8	1
1133	OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic TÂcell differentiation spectrum. Cell Reports Medicine, 2023, 4, 100939.	6.5	6
1134	CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer. Cancers, 2023, 15, 1262.	3.7	7
1135	Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6583-6599.	2.5	2
1136	Hypercholesterolemia Influences the Progression of Cancer by Changing the Biomolecular and Immunological Status of the Tumor Microenvironment. , 2023, , 1-30.		0
1137	X-ray irradiation negatively affects immune responses in the lymphatic network. Microvascular Research, 2023, 148, 104511.	2.5	1
1138	COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review. Journal of Immunotherapy and Precision Oncology, 2023, 6, 103-110.	1.4	0
1139	The temporal behavior of the murine T cell receptor repertoire following Immunotherapy. Scientific Data, 2023, 10, .	5.3	0
1140	Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2023, 14, 245-264.	1.4	2
1141	Novel biomaterials for stem cell engineering and bone regeneration. , 2023, , 169-204.		0

#	ARTICLE	IF	CITATIONS
1142	Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives. Journal of Controlled Release, 2023, 356, 14-25.	9.9	7
1143	The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study. Clinical Oncology, 2023, , .	1.4	3
1144	Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis. Open Life Sciences, 2023, 18, .	1.4	1
1145	Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database. Annals of Translational Medicine, 2023, 11, 163-163.	1.7	0
1146	β 3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN- γ -dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. Cancer Gene Therapy, 2023, 30, 890-904.	4.6	5
1147	CD39/CD73/A2AR pathway and cancer immunotherapy. Molecular Cancer, 2023, 22, .	19.2	43
1148	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
1149	Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis. Current Oncology, 2023, 30, 2997-3019.	2.2	3
1150	Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis. Frontiers in Oncology, 0, 13, .	2.8	3
1151	A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy. Advanced Healthcare Materials, 2023, 12, .	7.6	0
1152	Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response. Journal of the American Chemical Society, 2023, 145, 6007-6023.	13.7	35
1153	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology, 0, 14, .	4.8	1
1154	The construction of a novel ferroptosis-related lncRNA model to predict prognosis in colorectal cancer patients. Medicine (United States), 2023, 102, e33114.	1.0	0
1155	Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis. Frontiers in Immunology, 0, 14, .	4.8	2
1156	Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression. Journal of Clinical Investigation, 2023, 133, .	8.2	10
1157	Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2023, 23, 2041-2050.	3.6	1
1158	Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint. Scientific Reports, 2023, 13, .	3.3	6
1159	Application and Prospect between m6A and lncRNA in Pancreatic Cancer. Advances in Clinical Medicine, 2023, 13, 3883-3888.	0.0	0

#	ARTICLE	IF	CITATIONS
1160	Applications of immune checkpoint inhibitors (ICIs) in the medical fields. , 0, 36, 321-330.		0
1161	CAR-T cells therapy: a potential new strategy against prostate cancer. , 0, 36, 1468-1473.		0
1162	Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma. Journal of Translational Medicine, 2023, 21, .	4.4	7
1163	Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells. Cancer Research, 2023, 83, 1815-1833.	0.9	7
1164	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology, 2023, 14, .	2.1	2
1165	Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	2
1166	Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report. BMC Neurology, 2023, 23, .	1.8	1
1167	Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis. BMC Cancer, 2023, 23, .	2.6	3
1168	Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPÎ± Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules, 2023, 28, 3147.	3.8	6
1169	Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	4.8	0
1170	Anti-cancer therapeutic agents and carpal tunnel syndrome: Clinical, electrodiagnostic, and ultrasound findings in seven patients. Journal of Oncology Pharmacy Practice, 2024, 30, 38-45.	0.9	0
1171	Novel Systemic Approaches for the Management of Meningiomas. Neurosurgery Clinics of North America, 2023, , .	1.7	1
1172	Epidemiology of Melanoma. , 0, , .		0
1173	PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics, 2023, 13, 1876-1891.	10.0	2
1175	A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma. Scientific Reports, 2023, 13, .	3.3	0
1176	Ectopic expression of cGAS in <i>Salmonella typhimurium</i> enhances STING-mediated IFN-Î² response in human macrophages and dendritic cells. , 2023, 11, e005839.		1
1177	TFAP2A promotes cervical cancer via a positive feedback pathway with PDâ€™L1. Oncology Reports, 2023, 49, .	2.6	1
1178	Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2621-2635.	6.4	5

#	ARTICLE	IF	CITATION
1179	Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelialâ€“Mesenchymal Transition. Molecular Diagnosis and Therapy, 0, , .	3.8	0
1180	Mitochondrial metabolic reprogramming-mediated immunogenic cell death reveals immune and prognostic features of clear cell renal cell carcinoma. Frontiers in Oncology, 0, 13, .	2.8	1
1181	Pediatric Brain Tumours: Lessons from the Immune Microenvironment. Current Oncology, 2023, 30, 5024-5046.	2.2	3
1182	Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma. Biology, 2023, 12, 738.	2.8	0
1183	Preliminary Exploration of the Clinical Features and Immunological Correlation between TIGIT and Esophageal Squamous Cell Carcinoma. Journal of Biosciences and Medicines, 2023, 11, 350-362.	0.2	0
1184	Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis. , 2023, 40, .		0
1185	Comprehensive Analysis of the Expression, Prognostic Value, and Immune Infiltration Activities of GABRD in Colon Adenocarcinoma. Mediators of Inflammation, 2023, 2023, 1-22.	3.0	0
1186	Peptide-based PET imaging agent of tumor TIGIT expression. EJNMMI Research, 2023, 13, .	2.5	1
1187	Immune Infiltration in Tumor and Adjacent Non-Neoplastic Regions Codetermines Patient Clinical Outcomes in Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2023, 18, 1184-1198.	1.1	4
1188	Emerging Nanoâ€“Immunotherapeutic Approaches to Glioma. Small Structures, 2023, 4, .	12.0	0
1190	In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy. Frontiers in Pharmacology, 0, 14, .	3.5	0
1191	ĐŸŃfŃ...Đ»Đ,Đ1/2Đ3/4Ń–Đ1/2Ń,,Ń–Đ»ŃĈŃ,ŃĖŃfŃŽŃ‡Ń– Đ»Ń–Đ1/4Ń,,Đ3/4Ń†Đ,Ń,Đ; Đ1/2Đ3/4Đ2Ń– Đ2Đ,ĐºĐ»Đ,ĐºĐ, Ń+Đ1/4ŃfĐ1/2Đ3/4Ń		
1192	Phase I Study of SYN1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical Cancer Research, 2023, 29, 2435-2444.	7.0	16
1193	The impact of microbially modified metabolites associated with obesity and bariatric surgery on antitumor immunity. Frontiers in Immunology, 0, 14, .	4.8	1
1194	Advances in lung adenocarcinoma: A novel perspective on prognoses and immune responses of CENPO as an oncogenic superenhancer. Translational Oncology, 2023, 34, 101691.	3.7	0
1196	Combining WGCNA and machine learning to construct basement membrane-related gene index helps to predict the prognosis and tumor microenvironment of HCC patients and verifies the carcinogenesis of key gene CTSA. Frontiers in Immunology, 0, 14, .	4.8	4
1197	The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4. Pathology Research and Practice, 2023, 247, 154583.	2.3	1
1198	Advances in dendritic cell vaccination therapy of cancer. Biomedicine and Pharmacotherapy, 2023, 164, 114954.	5.6	13

#	ARTICLE	IF	CITATIONS
1199	Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment. <i>Immuno</i> , 2023, 3, 195-216.	1.5	0
1200	Targeting Wnt/ β 2-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity. <i>Heliyon</i> , 2023, 9, e16688.	3.2	4
1202	Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo. <i>AAPS Journal</i> , 2023, 25, .	4.4	1
1203	Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
1204	Combination Therapy as a Promising Way to Fight Oral Cancer. <i>Pharmaceutics</i> , 2023, 15, 1653.	4.5	2
1205	Immune-related biomarkers predict the prognosis and immune response of breast cancer based on bioinformatic analysis and machine learning. <i>Functional and Integrative Genomics</i> , 2023, 23, .	3.5	8
1206	Building Team Medicine in the Management of CNS Metastases. <i>Journal of Clinical Medicine</i> , 2023, 12, 3901.	2.4	0
1207	Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
1208	Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
1209	CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis. <i>Scientific Reports</i> , 2023, 13, .	3.3	6
1210	The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 595-601.	3.1	0
1211	Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. <i>Cancers</i> , 2023, 15, 3220.	3.7	10
1212	Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1170-1181.	2.5	4
1213	Gemini nanoparticles-based quadruple therapy (GNQT) achieved effective tumor immunotherapy by comprehensive regulation of tumor microenvironment. <i>Nano Today</i> , 2023, 51, 101915.	11.9	2
1214	Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022. , 2023, 64, 29.		1
1215	A pan-cancer analysis to provide insight into the immunological role and prognostic value of HTRA3. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2023, , .	0.9	0
1216	Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1217	Focalizing regions of biomarker relevance facilitates biomarker prediction on histopathological images. <i>IScience</i> , 2023, 26, 107243.	4.1	0

#	ARTICLE	IF	CITATIONS
1218	The expression and function of the <scp>B7</scp> family in <i>Helicobacter pylori</i> infection and gastric carcinogenesis process. <i>Helicobacter</i> , 2023, 28, .	3.5	1
1219	Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. <i>British Journal of Cancer</i> , 2023, 129, 24-37.	6.4	7
1220	Tumor Organoid and Spheroid Models for Cervical Cancer. <i>Cancers</i> , 2023, 15, 2518.	3.7	3
1221	Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1222	Oncogenic role and drug sensitivity of ETV4 in human tumors: a pan-cancer analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1223	Multi-shell structured upconversion nanocarriers that combine IDO inhibitor-induced immunotherapy with NIR-triggered photodynamic therapy for deep tumors. <i>Biomaterials Science</i> , 2023, 11, 4684-4699.	5.4	1
1224	Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemoâ€Immunoâ€Embolization for the Treatment of Hepatocellular Carcinoma. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	1
1225	Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 2700.	3.7	1
1226	Curcumin nanocarrier carrying si-TAR-RNA binding protein (TRBP) restricts development of hepatocellular carcinoma. <i>Materials Express</i> , 2023, 13, 407-413.	0.5	0
1227	The Dawn of a New Era: Targeting the â€œUndruggablesâ€ with Antibody-Based Therapeutics. <i>Chemical Reviews</i> , 2023, 123, 7782-7853.	47.7	13
1228	Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
1229	An Fc Binding Peptide-Based Facile and Versatile Build Platform for Multispecific Antibodies. <i>Nano Letters</i> , 2023, 23, 4191-4200.	9.1	4
1230	The predictive effect of immune therapy and chemotherapy under T cell-related gene prognostic index for Gastric cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	2
1231	Exploring the role of pyroptosis in shaping the tumor microenvironment of colorectal cancer by bulk and single-cell RNA sequencing. <i>Cancer Cell International</i> , 2023, 23, .	4.1	2
1232	Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (<scp>NIVOSQUACS</scp> study)â€Phase <scp>II</scp> data covering impact of concomitant haematological malignancies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1799-1810.	2.4	3
1233	Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review. <i>Medicina (Lithuania)</i> , 2023, 59, 991.	2.0	1
1234	Tumor Microenvironment Mediated Spermidine-Metal-Immuno peptide Nanocomplex for Boosting Ferroptotic Immunotherapy of Lymphoma. <i>ACS Nano</i> , 2023, 17, 10925-10937.	14.6	13
1235	Functional roles of sphingolipids in immunity and their implication in disease. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1110-1130.	7.7	9

#	ARTICLE	IF	CITATIONS
1236	A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. ESMO Open, 2023, 8, 101589.	4.5	2
1238	MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma. Aging, 0, , .	3.1	0
1239	A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Science Advances, 2023, 9, .	10.3	5
1240	Regulation of the tumor immune microenvironment by the Hippo Pathway: Implications for cancer immunotherapy. International Immunopharmacology, 2023, 122, 110586.	3.8	4
1241	Prognostic and immunological potential of PPM1G in lung adenocarcinoma. Molecular Medicine Reports, 2023, 28, .	2.4	1
1243	The development and benefits of metformin in various diseases. Frontiers of Medicine, 0, , .	3.4	1
1244	Doxorubicin prodrug-based nanomedicines for the treatment of cancer. European Journal of Medicinal Chemistry, 2023, 258, 115612.	5.5	8
1245	E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies. Frontiers in Immunology, 0, 14, .	4.8	1
1246	Systemic Neoadjuvant Therapies for Treatment of Cutaneous Squamous Cell Carcinoma of the Periorbital Region. International Ophthalmology Clinics, 2023, 63, 35-46.	0.7	0
1247	Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Science Advances, 2023, 9, .	10.3	10
1248	Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. BMC Cancer, 2023, 23, .	2.6	0
1249	Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy. Molecular Therapy - Nucleic Acids, 2023, 33, 376-390.	5.1	5
1250	Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. , 2023, 40, .		4
1251	Systematic Review and Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors in the Treatment of Prostate Cancer. International Journal of Cancer Management, 2023, In Press, .	0.4	0
1252	A Study on the Clinical Significance of Blood Exosomal PD-L1 in Non-Small Cell Lung Cancer Patients and its Correlation with PD-L1 in Tumor Tissues. Hormone and Metabolic Research, 0, , .	1.5	0
1253	Chimeric antigen receptor T cells for acute myeloid leukemia. European Journal of Haematology, 2024, 112, 28-35.	2.2	3
1254	Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer—A Large-scale Retrospective Study. Journal of Immunotherapy, 0, , .	2.4	0
1255	Identification and validation of a novel HOX-related classifier signature for predicting prognosis and immune microenvironment in pediatric gliomas. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	1

#	ARTICLE	IF	CITATIONS
1256	Ocular involvement in allergic drug reactions. Current Opinion in Allergy and Clinical Immunology, 0, , .	2.3	0
1258	A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?. Cureus, 2023, , .	0.5	1
1259	Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer. Biochemical Pharmacology, 2023, 215, 115724.	4.4	0
1260	Aptamer-Based Immune Drug Systems (AptIDCs) Potentiating Cancer Immunotherapy. Chemistry, 2023, 5, 1656-1680.	2.2	0
1261	Unveiling the Neural Environment in Cancer: Exploring the Role of Neural Circuit Players and Potential Therapeutic Strategies. Cells, 2023, 12, 1996.	4.1	1
1262	Metal-based drug delivery systems for cancer immunotherapy. , 2023, , 851-891.		0
1263	Identification and validation of a genetic risk signature associated with prognosis in clear-cell renal cell carcinoma patients. Medicine (United States), 2023, 102, e34582.	1.0	1
1264	Computational Identification of Most Deleterious Missense Mutations in Human PD-1 Gene. Scientific World Journal, The, 2023, 2023, 1-11.	2.1	0
1265	Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. International Journal of Molecular Sciences, 2023, 24, 12502.	4.1	1
1267	Higher cytotoxic activities of CD8+ T cells and natural killer cells from peripheral blood of early diagnosed lung cancer patients. BMC Immunology, 2023, 24, .	2.2	2
1268	<i>CACNA1C</i> mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma. Immunotherapy, 0, , .	2.0	0
1269	Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 325, H751-H767.	3.2	1
1270	Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance. Journal of Immunotherapy and Precision Oncology, 2023, , .	1.4	0
1271	Recent advances in targeted strategies for triple-negative breast cancer. Journal of Hematology and Oncology, 2023, 16, .	17.0	13
1272	Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity. ACS Nano, 2023, 17, 17554-17567.	14.6	2
1273	Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 15573-15588.	2.5	0
1274	The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Frontiers in Immunology, 0, 14, .	4.8	2
1275	Noninvasive <i>In Vivo</i> Imaging of T-Cells during Cancer Immunotherapy Using Rare-Earth Nanoparticles. ACS Nano, 2023, 17, 17908-17919.	14.6	2

#	ARTICLE	IF	CITATIONS
1276	Occurrence of irAEs after Immune Checkpoint Inhibitor Rechallenge: An Updated Meta-Analysis. Journal of Clinical Pharmacy and Therapeutics, 2023, 2023, 1-11.	1.5	0
1277	MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer. Nature Communications, 2023, 14, .	12.8	3
1278	Recent advances and future perspectives in the therapeutics of prostate cancer. Experimental Hematology and Oncology, 2023, 12, .	5.0	2
1279	Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. International Journal of Molecular Sciences, 2023, 24, 11694.	4.1	1
1280	Combined PD-L1/TGF β 2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nature Communications, 2023, 14, .	12.8	3
1281	Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nature Communications, 2023, 14, .	12.8	19
1282	Tumor Abnormality-Oriented Nanomedicine Design. Chemical Reviews, 2023, 123, 10920-10989.	47.7	9
1283	COL5A2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer based on transcriptomics and single-cell RNA sequencing. BMC Medical Genomics, 2023, 16, .	1.5	2
1284	Role of immune related genes in predicting prognosis and immune response in patients with hepatocellular carcinoma. Journal of Biochemical and Molecular Toxicology, 2024, 38, .	3.0	0
1285	miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration. Molecular Therapy - Oncolytics, 2023, 31, 100725.	4.4	3
1286	Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100852.	9.1	2
1287	Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer. Nature Communications, 2023, 14, .	12.8	2
1288	Case report: Identification of potential prognosis-related LAG3 overexpression and DICER1 mutation in pituitary carcinoma: two cases. Frontiers in Neuroscience, 0, 17, .	2.8	0
1289	The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity. Nature Immunology, 0, , .	14.5	2
1290	Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor. Materials Today Bio, 2023, 23, 100796.	5.5	0
1291	Integrative Analysis Reveals STC2 as a Prognostic Biomarker of Laryngeal Squamous Cell Carcinoma. Applied Biochemistry and Biotechnology, 0, , .	2.9	1
1292	The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nature Medicine, 2023, 29, 2814-2824.	30.7	5
1293	Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 17663-17670.	2.5	0

#	ARTICLE	IF	CITATIONS
1294	The Potential Role of the T2 Ribonucleases in TME-Based Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 2160.	3.2	0
1295	Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors. <i>Oncology</i> , 2023, 101, 537-541.	1.9	1
1296	Systemic Onco-Sphere: Host Neuronal System in Cancer. , 2023, , 511-534.		0
1297	Combining WGCNA and machine learning to construct immune-related EMT patterns to predict HCC prognosis and immune microenvironment. <i>Aging</i> , 2023, 15, 7146-7160.	3.1	0
1298	Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2023, , .	0.7	0
1299	Elucidating the role of T-cell exhaustion-related genes in colorectal cancer: a single-cell bioinformatics perspective. <i>Functional and Integrative Genomics</i> , 2023, 23, .	3.5	8
1301	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
1302	Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A _{2A} /A ₃ Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 12249-12265.	6.4	0
1303	Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1304	Synergistic Effect of Ginsenoside Rh2 Combines with Ionizing Radiation on CT26/luc Colon Carcinoma Cells and Tumor-Bearing Animal Model. <i>Pharmaceuticals</i> , 2023, 16, 1188.	3.8	0
1305	Restoration of Foxp3 ⁺ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 208, 879-895.	5.6	4
1306	Prognostic value and immunological role of CSNK1D in human cancers. <i>Aging</i> , 2023, 15, 8948-8975.	3.1	1
1307	Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC). <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-8.	3.0	1
1308	FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis. <i>Medicine (United States)</i> , 2023, 102, e35084.	1.0	0
1309	Discovery of Anti-CD47 Peptides as Innate Immune Checkpoint Inhibitors. <i>Advanced Therapeutics</i> , 2023, 6, .	3.2	0
1310	Pan-cancer analysis and experimental validation identify ndc1 as a potential immunological, prognostic and therapeutic biomarker in pancreatic cancer. <i>Aging</i> , 2023, 15, 9779-9796.	3.1	0
1311	Synergistic immunostimulation for tumor sensitization with a biomineralized DNA sponge. <i>Nano Today</i> , 2023, 52, 101996.	11.9	0
1312	Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 192, 104144.	4.4	0

#	ARTICLE	IF	CITATIONS
1313	Prospective pharmacological potential of cryptotanshinone in cancer therapy. Pharmacological Research Modern Chinese Medicine, 2023, 9, 100308.	1.2	0
1314	Dose-Specific Intratumoral GM-CSF Modulates Breast Tumor Oxygenation and Antitumor Immunity. Journal of Immunology, 2023, 211, 1589-1604.	0.8	2
1315	The pan-cancer multi-omics landscape of key genes of sialylation combined with RNA-sequencing validation. Computers in Biology and Medicine, 2023, 166, 107556.	7.0	1
1316	Unlocking the potential of the tumor microenvironment for cancer therapy. Pathology Research and Practice, 2023, 251, 154846.	2.3	1
1317	A nanobody based ultrasensitive electrochemical biosensor for the detection of soluble CTLA-4 â€“A candidate biomarker for cancer development and progression. Biosensors and Bioelectronics, 2023, 242, 115733.	10.1	1
1318	Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis. Frontiers in Oncology, 0, 13, .	2.8	1
1319	Correlation Analysis of Prognostic Gene Expression, Tumor Microenvironment, and Tumor-Infiltrating Immune Cells in Ovarian Cancer. Disease Markers, 2023, 2023, 1-24.	1.3	0
1320	Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients. Translational Oncology, 2023, 38, 101799.	3.7	3
1321	Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model. Cancers, 2023, 15, 4931.	3.7	0
1322	2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report. Frontiers in Oncology, 0, 13, .	2.8	0
1323	Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. International Journal of Molecular Sciences, 2023, 24, 15072.	4.1	2
1324	Cancerâ€derived nonâ€coding <scp>RNAs</scp> endow tumor microenvironment with immunosuppressive properties. Wiley Interdisciplinary Reviews RNA, 2024, 15, .	6.4	2
1325	Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice. Cells, 2023, 12, 2439.	4.1	0
1326	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	4.2	4
1327	Development of pauci-immune necrotizing glomerulonephritis during pembrolizumab treatment. Clinical and Experimental Nephrology, 0, , .	1.6	0
1329	Cancer-on-chip models for metastasis: importance of the tumor microenvironment. Trends in Biotechnology, 2023, , .	9.3	2
1330	Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies. Cancers, 2023, 15, 5468.	3.7	0
1331	Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation. Frontiers in Immunology, 0, 14, .	4.8	2

#	ARTICLE	IF	CITATIONS
1332	Mirabegron displays anticancer effects by globally browning adipose tissues. <i>Nature Communications</i> , 2023, 14, .	12.8	0
1333	A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer. <i>Discover Oncology</i> , 2023, 14, .	2.1	1
1334	Sialic Acid-Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy. <i>Small</i> , 0, , .	10.0	0
1335	Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity. <i>Science Advances</i> , 2023, 9, .	10.3	1
1336	Immune checkpoint inhibitors for multiple myeloma immunotherapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	2
1337	Biology-aware mutation-based deep learning for outcome prediction of cancer immunotherapy with immune checkpoint inhibitors. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	0
1338	Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells. <i>Molecular Immunology</i> , 2023, 164, 98-111.	2.2	1
1339	Understanding the Impact of Population and Cancer Type on Tumor Mutation Burden Scores: A Comprehensive Whole-Exome Study in Cancer Patients From India. <i>JCO Global Oncology</i> , 2023, , .	1.8	0
1340	Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy. <i>Mathematical Biosciences</i> , 2023, 366, 109106.	1.9	0
1342	Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study. <i>Journal of Immunotherapy</i> , 2024, 47, 1-6.	2.4	0
1343	The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 1121-1134.	3.1	0
1344	Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1345	Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	1.0	0
1346	Regulatory role of RGMb in lung injury promoted by the combination of carbon ion irradiation and anti-PD-1 antibody through Erk1/2 and p38 MAPK pathways. <i>Biochemical and Biophysical Research Communications</i> , 2024, 691, 149334.	2.1	0
1349	Imaging of abdominopelvic oncologic emergencies. <i>Abdominal Radiology</i> , 2024, 49, 823-841.	2.1	0
1350	Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy. <i>Small Methods</i> , 0, , .	8.6	0
1351	A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer. <i>Cancer Biomarkers</i> , 2023, , 1-15.	1.7	0
1352	Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles. <i>Advanced Science</i> , 2024, 11, .	11.2	0

#	ARTICLE	IF	CITATIONS
1353	The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1354	Multifunctional Probe Based on “Chemical Antibody” Aptamer for Noninvasive Detection of PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 0, , .	4.6	0
1355	Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy. <i>Materials Today Bio</i> , 2024, 24, 100926.	5.5	0
1356	Hepatocellular Carcinoma and Human Gut Microbiome: Association with Disease and Scope for Therapeutic Intervention. , 2023, , 127-149.		0
1358	Cosmosiin Induces Apoptosis in Colorectal Cancer by Inhibiting PD-L1 Expression and Inducing ROS. <i>Antioxidants</i> , 2023, 12, 2131.	5.1	0
1359	Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity. <i>Cancer Treatment and Research</i> , 2023, , 95-142.	0.5	0
1360	A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy. <i>Cancer Research</i> , 2024, 84, 626-638.	0.9	0
1362	Pirin Inhibits FAS-Mediated Apoptosis to Support Colorectal Cancer Survival. <i>Advanced Science</i> , 2024, 11, .	11.2	0
1363	Co-culture platform for tuning of cancer receptor density allows for evaluation of bispecific immune cell engagers. <i>New Biotechnology</i> , 2024, 79, 120-126.	4.4	0
1364	Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. <i>Oncologie</i> , 2024, 26, 9-25.	0.7	0
1366	Prognosis stratification and response to treatment in breast cancer based on one-carbon metabolism-related signature. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1367	Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma. <i>Genes and Genomics</i> , 2024, 46, 171-185.	1.4	0
1368	Immunotherapy for lung cancer. <i>Pathology Research and Practice</i> , 2024, 254, 155104.	2.3	0
1369	Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor. <i>Journal of Immunology</i> , 2024, 212, 917-927.	0.8	0
1370	Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. <i>Cancers</i> , 2024, 16, 435.	3.7	0
1371	Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models. <i>Journal of Medicinal Chemistry</i> , 2024, 67, 2188-2201.	6.4	0
1372	Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response. <i>Breast Cancer Research</i> , 2024, 26, .	5.0	0
1373	Infection-related Hospitalizations During Immune Checkpoint Inhibitor Treatment Without Immunosuppressants. <i>Journal of Immunotherapy</i> , 2024, 47, 139-147.	2.4	0

#	ARTICLE	IF	CITATIONS
1374	Recent advances in light-triggered cancer immunotherapy. Journal of Materials Chemistry B, 2024, 12, 2650-2669.	5.8	0
1375	Coexistence of Anti-Hu and Anti-SOX1 Autoantibodies in Atezolizumab-related Encephalitis. Journal of the Korean Neurological Association, 2024, 42, 48-52.	0.1	0
1376	Evaluating the Mechanism of Cell Death in Melanoma Induced by the Cannabis Extract PHEC-66. Cells, 2024, 13, 268.	4.1	0
1377	LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets. Biomolecules, 2024, 14, 187.	4.0	0
1378	Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer. Journal of Translational Medicine, 2024, 22, .	4.4	0
1379	Overexpression of SPP1 is a prognostic indicator of immune infiltration in lung adenocarcinoma. Aging, 0, , .	3.1	0
1380	Hypoxia-derived molecular subtype and gene signature characterize prognoses and therapeutic responses in head and neck squamous cell carcinoma. Medicine (United States), 2024, 103, e37233.	1.0	0
1381	Immunotherapy Toxicity Management in Clinical Practice. Rheumatic Disease Clinics of North America, 2024, 50, 229-239.	1.9	0
1382	The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors. Nature Cancer, 0, , .	13.2	1
1384	Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises. Cells, 2024, 13, 337.	4.1	0
1385	Translational bioinformatics approach to combat cardiovascular disease and cancers. Advances in Protein Chemistry and Structural Biology, 2024, , 221-261.	2.3	1
1386	Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma. Scientific Reports, 2024, 14, .	3.3	0
1387	TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association. Scientific Reports, 2024, 14, .	3.3	0
1388	Immune checkpoint inhibitors and acute kidney injury. Frontiers in Immunology, 0, 15, .	4.8	0
1389	Radiation-Activated Resiquimod Prodrug Nanomaterials for Enhancing Immune Checkpoint Inhibitor Therapy. Nano Letters, 2024, 24, 2921-2930.	9.1	0
1390	A Review of Immunotherapy in the Treatment of Tumors. Immunology Studies, 2024, 06, 11-14.	0.0	0
1391	Targeting the NF- κ B pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cellular and Molecular Life Sciences, 2024, 81, .	5.4	0
1392	Recent advances in NO-triggered gas therapy by metal-organic frameworks. Materials Today Chemistry, 2024, 36, 101964.	3.5	0

#	ARTICLE	IF	CITATIONS
1393	Bioinformatics analysis and clinical significance of NRP-1 in triple-negative breast cancer. Heliyon, 2024, 10, e27368.	3.2	0
1394	The role of the BTLA–HVEM complex in the pathogenesis of breast cancer. Breast Cancer, 2024, 31, 358-370.	2.9	0
1395	Engineered bacteria in tumor immunotherapy. Cancer Letters, 2024, 589, 216817.	7.2	0
1396	Engineering multifunctional dynamic hydrogel for biomedical and tissue regenerative applications. Chemical Engineering Journal, 2024, 487, 150403.	12.7	0
1398	Nephroblastoma-specific dysregulated gene SNHG15 with prognostic significance: scRNA-Seq with bulk RNA-Seq data and experimental validation. Discover Oncology, 2024, 15, .	2.1	0
1399	Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics. Indian Journal of Otolaryngology and Head and Neck Surgery, 0, , .	0.9	0
1400	Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications. MedComm, 2024, 5, .	7.2	0
1401	Comprehensive analysis indicated that <scp>NDE1</scp> is a potential biomarker for panâ€cancer and promotes bladder cancer progression. Cancer Medicine, 2024, 13, .	2.8	0
1402	Novel biomarkers of inflammation-associated immunity in cervical cancer. Frontiers in Oncology, 0, 14, .	2.8	0
1403	An artificial intelligenceâ€powered <scp>PDâ€L1</scp> combined positive score (<scp>CPS</scp>) analyser in urothelial carcinoma alleviating interobserver and intersite variability. Histopathology, 0, , .	2.9	0
1404	Promising dawn in tumor microenvironment therapy: engineering oral bacteria. International Journal of Oral Science, 2024, 16, .	8.6	0
1405	Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect. International Journal of Nanomedicine, 0, Volume 19, 2793-2806.	6.7	0
1406	LAG-3 Inhibitors for the Treatment of Lung Cancer. , 2024, , 131-152.		0
1407	Birinapant Reshapes the Tumor Immunoepitome and Enhances Antigen Presentation. International Journal of Molecular Sciences, 2024, 25, 3660.	4.1	0
1409	PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site. International Journal of Clinical Oncology, 0, , .	2.2	0
1410	PERP May Affect the Prognosis of Lung Adenocarcinoma by Inhibiting Apoptosis. Cancer Management and Research, 0, Volume 16, 199-214.	1.9	0